 
 
Glutamatergic and GABAergic Biomarkers in 
rTMS for Adolescent Depression  
 
[STUDY_ID_REMOVED]  
 
26JUL2021  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
1 
 Glutamatergic and GABAergic Biomarkers in rTMS for Adolescent Depression  
 
 
Principal Investigator : 
 
[INVESTIGATOR_68231], MS  
Department of Psychiatry and Psychology  
Mayo Clinic  
[ADDRESS_74354] SW  
[COMPANY_002]ster, MN [ZIP_CODE]  
 
 
 
[EMAIL_1315]  
  
 
Co-Investigator(s)  
 
 
Department of Psychiatry and Psychology  
Mayo Clinic  
[ADDRESS_74355] SW  
[COMPANY_002]ster, MN [ZIP_CODE]  
 
 
 
  
Center for Magnetic Resonance Research  
University of Minnesota – Minneapolis  
[ADDRESS_74356] SE  
Minneapolis, MN  [ZIP_CODE]  
 
 
 
 
(Biostatistician)  
Associate [CONTACT_3348] of Clinical Sciences  
Division of Biostatistics   

Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74357] SW  
[COMPANY_002]ster, MN [ZIP_CODE]  
 
 
 
Funding Sponsor:  
 
National  Institute of Mental Health  
(1R01 MH113700)  
 
Neuronetics, Inc.  
(Grant -in-kind for equipment s upport)  
 
 
Study Product:  NeuroStar TMS Therapy® System in 
XPLOR research configuration  
Protocol Number:    May Clinic IRB# 17-004958   
IDE Number:   
 G170212  
 

Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
3 
  
 
 Protocol Date  6 June 2018 Version ( 3.0)  
 
Version 
No. Date  Major Changes  
1 16Sept2017  Initial  
2 26Sept2017  DSMB recommended changes  
3 6June2018  Add MRI/MRS portion and other recommendations from NIMH 
monitor report  
[ADDRESS_74358] 
burden/ use of i2b2 as a recruitment tool/ IRB approved phone 
script, email and contact [CONTACT_68266]  
5 20Jan2020  Blurred Vision: FDA requested protocol changes/added side effect 
“blurred vision” to consent form/changes in AE documentation  
6 26 July 2021  The FDA recommended additional screening and monitoring for 
extrapyramidal twitching/trembling prior to starting the study 
procedures and throughout the study. The Abnormal Involuntary 
Movement Scale (AIMS) will be collected at the screening visit 
and at weekly assessments during Phase I and II investigational 
treatments and at the 6 month posttreatment visit.  
   
 
  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
4 
 Table of Contents  
STUDY SUMMARY  ................................ ................................ ................................ ................................ .  
1 INTRODUCTION  ................................ ................................ ................................ ............................   
1.1 BACKGROUND  ................................ ................................ ................................ ................................ ..........  1.2
 INVESTIGATIONAL DEVICE  ................................ ................................ ................................ ............................   
1.3 PRECLINICAL DATA ................................ ................................ ................................ ................................ .. 1.4
 CLINICAL DATA TO DATE................................ ................................ ................................ .........................  1.5
 STUDY RATIONALE AND RISK ANALYSIS (RISKS TO BENEFITS RATIO ) ................................ .........................   
1.5.1  Study Rationale  ................................ ................................ ................................ ..............  1.5.2
 Anticipated Risks  ................................ ................................ ................................ ..................   
1.5.3  Potential Benefits  ................................ ................................ ................................ ..................   
1.6 ANTICIPATED DURATION OF THE CLINICAL INVESTIGATION  ................................ ................................ .........   
2 STUDY OBJECTIVES  ................................ ................................ ................................ ....................  3
 STUDY DESIGN  ................................ ................................ ................................ ..............................   
3.1 GENERAL DESIGN ................................ ................................ ................................ ................................ ..... 3.2
 PRIMARY STUDY ENDPOINTS  ................................ ................................ ................................ ........................   
3.3 SECONDARY STUDY ENDPOINTS ………………………………………………………………………….  
3.4 PRIMARY SAFETY ENDPOINTS  ................................ ................................ ................................ .......................   
4 PARTICIPANT  SELECTION, ENROLLMENT AND WITHDRAWAL  ................................ .........   
4.1 INCLUSION CRITERIA  ................................ ................................ ................................ ................................  4.2
 EXCLUSION CRITERIA  ................................ ................................ ................................ ................................ ...  
4.3 PARTICIPANT  RECRUITMENT , ENROLLMENT AND SCREENING  ................................ ................................ ......  
4.4 EARLY WITHDRAWAL OF PARTICIPANT S ................................ ................................ ................................ .......  
4.4.1  When and How to Withdraw Participant …………………………………………………………………..  
4.4.2  Data Collection and Follow -up for Withdrawn Participant ……………………………………………  
5 STUDY DEVICE  ................................ ................................ ................................ .............................   
5.1
 DESCRIPTION …………………………………………………………………………………………….. 5.
2 METHOD FOR ASSIGNING PARTICIPANT S TO TREATMENT GROUPS  ................................ ...............................   
5.3 PREPARATION AND ADMINISTRATION /IMPLANTATION OF INVESTIGATIONAL DEVICE ………………. 5.4
 PACKAGING AND LABELING  ................................ ................................ ................................ .....................  5.5
 MASKING /BLINDING OF STUDY  ................................ ................................ ................................ .....................   
5.6 RECEIVING , STORAGE , DISTRIBUTION AND RETURN ……………………………………………………..  
6 STUDY PROCEDURES  ................................ ................................ ................................ ...................   
6.1 VISIT 1………………………………………………………………………………………………… 6.2
 VISIT 2…………………………………………………………………………………………………  
    6.3          Daily Visits……………………………………………………………………………………………  
7 STATISTICAL PLAN  ................................ ................................ ................................ ......................   
7.1 SAMPLE SIZE DETERMINATION  ................................ ................................ ................................ .....................   
7.2 STATISTICAL METHODS ................................ ................................ ................................ ................................ .  
8 SAFETY AND ADVERSE EVENTS  ................................ ................................ ...........................  ….. 
8.1 DEFINITIONS  ................................ ................................ ................................ ................................ .............  8.2
 RECORDING OF ADVERSE EVENTS ................................ ................................ ................................ ............  8.3
 SPONSOR -INVESTIGATOR REPORTING OF UNANTICIPATED ADVERSE DEVICE EFFECTS AND 
UNANTICIPATED PROBLEMS  ................................ ................................ ................................ ................................ ........   
8.3.1  Sponsor -Investigator Reporting, Notifying Mayo IRB  ................................ ........................  8.3.2
 Sponsor -Investigator Reporting: Notifying the FDA  ................................ ................................ .  
         8.3.3      Deviations From Investigational Plan……………………………………………………………..  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
5 
 8.4 UNBLINDING PROCEDURES (BREAKING THE BLIND ) (AS NECESSARY IF THE STUDY IS BLINDED ) ..................   
8.5 STOPPI[INVESTIGATOR_16442]  ................................ ................................ ................................ ................................ ...... 8.6
 MEDICAL MONITORIN G………………………………………………………………………………….  
8.6.[ADDRESS_74359]  ................................ .............  …………………  
[ADDRESS_74360] KEEPI[INVESTIGATOR_1645]  ................................ ................................ ...............   
9.1 CONFIDENTIALITY  ................................ ................................ ................................ ................................ .... 9.2
 SOURCE DOCUMENTS  ................................ ................................ ................................ ................................ ....  
9.3 CASE REPORT FORMS  ................................ ................................ ................................ ................................ ....  
9.4 DATA  MANAGEMENT  ................................ ................................ ................................ .............................   
    9.5         DATA SECURITY AND CONFIDENTIALITY…………………………………………………… ..…    
9.6          Records Retention………………………………………………………………………………………..  
10 STUDY MONITORING, AUDITING, AND INSPECTING  ................................ .............................   
10.1 STUDY MONITORING PLAN ................................ ................................ ................................ .......................  61 
10.2 AUDITING AND INSPECTING  ................................ ................................ ................................ ...........................   
11 ETHICAL CONSIDERATIONS  ................................ ................................ ................................ ... 12
 STUDY FINANCES  ................................ ................................ ................................ .........................   
12.1 FUNDING SOURCE  ................................ ................................ ................................ ................................ .. 12.2
 PARTICIPANT  STIPENDS OR PAYMENTS  ................................ ................................ ................................ .........   
13 PUBLICATION PLAN  ................................ ................................ ................................ .................  14
 REFERENCES  ................................ ................................ ................................ .............................  15
 ATTACHMENTS  (APPENDIX A)  ................................ ................................ ................................ ...  
16     ATTACHMENTS (APPENDIX B)……………………………………………………………………..   
 
 
 
 
  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74361] OF ABBREVIATIONS  
AE Adverse Event/Adverse Experience  
ATHF  Antidepressant Treatment History Form.  
BDI-II Beck Depression Inventory -II 
CDRS -R Children’s Depression Rating Scale, Revised  
CFR  Code of Federal Regulations  
CGI-S Clinical Global Impression -Severity Scale  
CRF  Case Report Form  
CSP Cortical Silent Period  
C-SSRS  Columbia Suicide Severity Rating Scale  
CTQ  Childhood Trauma Questionnaire  
DSMB  Data and Safety Monitoring Board  
FDA  Food and Drug Administration  
GABA  Gamma aminobutyric acid  
HIPAA  Health Insurance Portability and Accountability Act  
Hz Hertz  
ICF Intracortical facilitation  
IDE Investigational Device Exemption  
IRB Institutional Review Board  
cTBS  Continuous Theta Burst Stimulation  
iTBS  Intermittent Theta Burst Stimulation  
LDLPFC  Left Dorsolateral Prefrontal Cortex  
LICI  Long Interval Intracortical Inhibition  
MDD  Major Depressive Disorder  
MEP  Motor Evoked Potential  
MINI  Mini International Neuropsychiatric Interview  
ms Millisecond  
MRI  Magnetic Resonance Imaging  
MRS  Magnetic Resonance Spectroscopy  
MT Motor Threshold  
NIH National Institute of Health  
NIMH  National Institute of Mental Health  
PDS Pubertal Development Scale and Tanner Staging  
PI [INVESTIGATOR_17107] -A17-SR Quick Inventory of Depressive Symptoms  
 Adolescent Self -Report  
RDLPFC  Right Dorsolateral Prefrontal Cortex  
rTMS  Repetitive Transcranial Magnetic Stimulation  
SAE  Serious Adverse Event/Serious Adverse Experience  
SHAPS  Snaith-Hamilton Pleasure Scale  
SIT-R3 Slosson Intelligence Test – Revised  
SICI  Short Interval Intracortical Inhibition  
SOP Standard Operating Procedure  
TASS  Transcranial Magnetic Stimulation Adult Safety Screen  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74362]  
UPI[INVESTIGATOR_68232] # 17 -004958   
 Version  6 Date:  [ADDRESS_74363] stimulation (TBS) . Please note 
that transcranial magnetic stimulation (TMS) biomarkers will be 
collected in this protocol during the course of the proposed 
interventions. Participants in Phase I  will also be offered   3 and 7 Tesla 
Magnetic Resonance Imaging (MRI) and Magnetic Resonance 
Spectroscopy (MRS)  scans  at the University of Minnesota Center for 
Magnetic Resonance Research.  
Overall Study 
Duration  5 years  
Participant Time 
Commitment  Phase I – 6 months (1 week  screening, 6 weeks of active treatment, 6 
month follow up visit)  
 
Phase II - 6 months (1 week screening, 2 weeks of active treatment, 6 
month follow up visit)  
Objectives  To perform an  effectiveness and target validation trial of 1 Hz vs. 10 Hz 
rTMS with a randomized, biomarker -stratified design. The target 
engagement and stratification biomarker is intracortical facilitation 
(ICF) a measure of glutamatergic tone in the brain.   Cortical GABA, 
glutamate, and glutamine measured with 7 Tesla MRS will be collected 
in healthy controls at baseline and depressed participants at baseline and 
after 6 weeks of TMS treatment in phase I.   
Number of 
Participants  Phase I - 120 participants  
Phase II - 50 participants  (maximum)  
MRI – 100 Depressed Subjects (Must be Eligible for Phase I)  
             30 Healthy Controls  
Diagnosis and Main 
Inclusion Criteria  Depressed adolescent (ages 12 -18) participants with moderate to severe 
major depressive disorder (MDD) defined by a score of 40 or greater on 
the Children’s Depression Rating Scale, Revised (CDRS -R) and an 
interview with the Mini International Neuropsychiatric Interview 
(MINI).  
Study Device  NeuroStar® TMS Therapy System in XPLOR research configuration  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
9 
 Duration of 
Exposure  Phase  I - 6 weeks (30 session s) and 3 week taper ([ADDRESS_74364] week 
of the taper).  Based on randomization participants will either receive 
sessions of 1 Hz rTMS at 120 % motor threshold (MT) with 2 400 
continuous pulses or 10 Hz rTMS at 120 % MT with 4  seconds on and 
36 seconds off for 2400 pulses.  Both 1 Hz and 10 Hz rTMS sessions 
will be delivered to the left dorsolateral prefrontal cortex (LDLPFC).  
 
Phase II - 2 weeks (10 sessions) of continuous theta burst ( cTBS ) or 
intermittent theta burst  (iTBS ) based on biomarker (ICF) status.  Note 
that TBS sessions involve  the delivery of 3 pulses of 50 Hz stimulation 
given every 200 milliseconds (ms) or 5 Hz.   Participants assigned to 
cTBS will receive 10 daily  sessions  (5 sessions per week for two weeks) 
with 120 second trains of uninterrupted TBS for 1800 pulses at 80% 
MT. Participants assigned to  iTBS will receive 10 daily  sessions  (5 
sessions per week for two weeks ) with 2 second trains every 10 seconds 
for a total of 570 seconds for 1800 pulses.  Both cTBS and iTBS 
sessions will be  delivered to the LDLPFC.  
  
NeuroStar TMS is not an implant.  Stimulation is delivered during the 
daily sessions in the neurostimulation suite.   
Reference therapy  Not Applicable  
Statistical 
Methodology  For the primary aim, a linear mixed model analysis of repeated 
measures will be used to evaluate the repetitive transcranial magnetic 
stimulation ( rTMS ) by [CONTACT_68267] (CDRS -R score) over 6 weeks of rTMS.  
 
For the secondary aim, a within -participant  linear mixed model analysis 
of repeated measures will be used to examine the change in ICF over 6 
weeks of rTMS . 
 
For the exploratory aim s, a within -subjects linear mixed model analysis 
of repeated measures will be used to examine the change in cortical 
MRS measures of GABA, glutamate, and glutamine over 6 weeks of 
rTMS treatment in depressed adolescents.  A multiple  
mediation/moderation path analytic model will be used to estimate the 
direct effect as well as the total and specific indirect effects of rTMS 
treatment on depression severity (at the 6 -week endpoint) through each 
potential baseline moderator (anhedonia and adversity).    
 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74365] with precision medicine approaches and intervention 
development.  Certain types of t ranscranial magnetic stimulation (TMS) provide noninvasive 
measures o f cortical GABAergic and glutamategeric tone.26-28 There are different types of TMS.  
Repetitive TMS (rTMS) delivers multiple pulses per session over many days or weeks for 
therapeutic purposes.  The effects of rTMS can also be studied as a probe of brain function.   
Theta burst stimulation (TBS) is a form of rTMS that is thought to have more rapid effects on  
synaptic plasticity and clinical symptoms  than standard rTMS.  Single and paired -pulse TMS 
paradigms are used to study the physiology of the brain.  Neurophysiological measures collected 
with transcran ial magnetic stimulation (TMS) such as intracortical facilitation (ICF), short -
interval intracortical inhibition (SICI), long -interval intracortical inhibition (LICI), and the 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
11 
 cortical silent period (CSP) are noninvasive measures of cortical GABAergic and glutamatergic 
tone.28-[ADDRESS_74366] presentations of depression are typi[INVESTIGATOR_68233] (10 Hz) rTMS applied to the LDLPFC  as this dosing approach 
has been widely studied.37,38  However, prior literature suggests that low frequency (1 Hz) rTMS 
applied to the right dorsolateral prefrontal cortex (RDLPFC) may be equally effective with 
superior tolerability.39-[ADDRESS_74367] 
variable responses to these two dosing strategies (1 Hz vs. 10 Hz) necessitating a more 
sophisticated neurobiological understanding and precision medicine approaches .34,[ADDRESS_74368] rTMS dosing approaches (1 Hz and 10 Hz) is an ethical and scientific 
prerequisite for future large , pi[INVESTIGATOR_68234].51,52   
Currently our group is leading a multicenter randomized, sham -controlled trial of rTMS for 
adolescent depression (A Randomized, Sham -Controlled Trial Evaluation of the Safety and 
Effectiveness of NeuroStar Transcranial Magnetic Stimulation (TMS) Therapy in Depressed 
Adolescents).  Phase I of the study is a 6 week (30 treatment sessions), randomized, sham -
controlled study of 10 Hz rTMS delivered to the left dorsolateral prefrontal cortex (LDLPC).  
The rTMS is targeted and dosed with the abductor pollicis brevis, “5 -cm rule.”  Phase II is a [ADDRESS_74369], the industry supported study design replicates a longstanding flaw of 
interventional work in children and adolescents (spanning psychotherapy, pharmacology, and 
novel therapeutics) in which adult protocols and dosing schedules are simply applied to children 
or adolescents.6-8  Second, the current industry supported clinical trial will not inform target 
engagement efforts nor advance understanding of the neurobiological underpi[INVESTIGATOR_68235] # 17 -004958   
 Version  6 Date:  [ADDRESS_74370], there is a paucity of data on low 
frequency (1 Hz) rTMS in adolescents and in general.9-[ADDRESS_74371] designed an effectiveness and target validation trial of 1 
Hz vs. 10 Hz rTMS. While the inclusion of a sham arm would be ideal, there are substantial 
pragmatic and financial barriers to completing such a study as a single site while concurrently 
addressing other critical National Institute of Mental Health (NIMH) priorities. Studies of [ADDRESS_74372] been studied with insufficient clinical characterization .33,52  
Anhedonia54 and adversity55,56 in depressed adolescents are important dimensional traits to 
quantify in terms of GABAergic tone, glutamatergic tone, and treatment responsivity to 1 Hz and 
10 Hz rTMS.  Examining a cohort of depressed adolescents and healthy controls with TMS 
neurophysiology would deepen our understanding of the role of GABA and glutamate in the 
negative valence systems domain.56,57  
 
Prior work demonstrates that anhedonia is a marker of treatment resistance, poor outcomes, and 
suicidality.  For example, recent multivariate analyses from the landmark Treatment of Resistant 
Depression in Adolescents (TORDIA) study identified a dimensional measure of anhedonia as 
the primary predictor of increased time to remission and decreased depression -free days in a 
large (n=334) cohort of adolescents with treatment resistant depression.[ADDRESS_74373] 
in the development of targeted, neurobiologically informed treatments.8,9  
 
 
MRS Biomarkers of GABAergic and Glutamatergic Tones in rTMS Studies  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
13 
  
Prior work demonstrated that the glutamine to glutamate ratio (Gln/Glu) is a sensitive measure of 
cortical glutamate -glutamine cycle dysfunction in severe psychiatric disorders. In our prior MRS 
study, 6 weeks of 10 Hz rTMS modulated cortical glutamatergic tone in depressed adolescents.  
Baseline, posttreatment, and 6 month follow up MRS 3 T scans examined glutamate 
concentrations in 8 cm voxels from the left dorsolateral prefrontal and anterior cingulate cortices   
(Figure 1).  Spectroscopic data were collected with an optimized, intermediate echo time, point 
resolved spectroscopy (PRESS) sequence and [ADDRESS_74374]/Glu ratios increased from baseline and at [ADDRESS_74375]/Glu ratio in the dorsolateral prefrontal cortex ( b̂ = –0.[ZIP_CODE]; 95% CI, –
0.[ZIP_CODE] to –0.[ZIP_CODE]; raw P=.003; false discovery rate P=.01).  Hence, throughout treatment and 
follow -up period, decreases in depressive symptom severity had an indirect relationship to 
increases in the Gln/Glu ratio.  This initial work presents many unanswered questions.  
Resolving GABA, glutamate, and glutamine at 3 T in a single acquisition is challenging to 
impossible. Special techniques can be used to quantify each of the neurochemicals separately, 
but that results in three different acquisitions which dramatically increases acquisition time.  Our 
current methodologies do not adequately resolve cortical GABA concentrations and may yield 
imprecise measures of glutamine concentrations as Cramer -Rao lower bounds (CRLB) criteria 
are suboptimal.  Current work with 7 T MRS demonstrates promise in resolving and quantifying 
GABA, glutamate, and glutamine in a single acquisition. To our knowledge, 7 T MRS has not 
been used to study adolescent depression previously.63,64 
 
Ultra -High Field MRS for Biomarker Development in Adolescent Depression  
 
Recent work in adult humans with 7 T MRS and stimulated echo acquisition mode (STEAM) 
sequence has enhanced the detection and resolution of glutamate, glutamine and GABA 
(Figure 2). In young adults (18 to 22 years of age), glutamate and glutamine could be quantified 
separately in the early visual cortex with very low CRLB of 2.0% ± 0 and 2.7 ± 0.3%, 
respectively which is not possible at 3 T.  Additionally, GABA was quantified with CRLB of 
13.5 ± 4.6%.  The spectra were acquired in [ADDRESS_74376] 
placed in the early visual cortex with STEAM sequence (TR = 5 s, TE = 8 ms, number of 
averages = 64). Additionally, quantified glutamate, glutamine and GABA concentrations from 
spectra acquired at TE of 8 ms removes a possible confound of changing T2.  Good quality data 
can be obtained in the frontal lobe using a prototype coil .63,64  
1.2 Investigational Device  
 
The NeuroStar ™ XPLOR® TMS Therapy System  will be used to deliver all of the proposed 
investigational rTMS sessions (1 Hz, 10 Hz, cTBS , and iTBS).  The NeuroStar ™ XPLOR® TMS 
Therapy System is a clinical research option for the NeuroStar ™ TMS Therapy System that 
provides features necessary to conduct randomized trials and other TMS research.  The 
NeuroStar ™ TMS Therapy System is a computerized electromechanical instrument that 
produces and delivers brief duration, rapi[INVESTIGATOR_68236] (pulsed) magnetic fields to induce 
electrical currents in localiz ed regions of the cerebral cortex for use in the treatment of MDD  in 
adults who have failed to receive benefit from  antidepressant medications .  The XPLOR® 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
14 
 research configur ation consists of three coils: a known -active coil identical to the NeuroStar ™ 
TMS System treatment coil and two identical, “blinded” coils.  One of the blinded coils provides 
active treatment identical to the known -active NeuroStar ™ TMS system treatment coil; the sham 
coil provides acoustically indistinguishable (from active) pulses and a gentle percussive 
sensation that simulates scalp sensations produced during active treatment.  Please note that the 
sham and blinded coils will not be used in this protocol.  
 
The proposed study also involves the investigational use of the Magstim Model [ADDRESS_74377] communicated that single and paired -pulse TMS biomarker studies do not 
fall into the scope of Investigational Device Exemption (IDE) regulation and do not require an 
IDE application.  Data collected with the Magstim Model [ADDRESS_74378] the proposed TMS biomarkers : motor threshold 
(MT), short interval intracortical inhibition (SICI) , intracortical facilitation (ICF), long interval   
intracortical inhibition (LICI), and cortical silent period (CSP).  The Magstim Model [ADDRESS_74379] components:  
 
a. A high current pulse generator producing currents of approximately 5,000 amps.  
b. A stimulating coil producing magnetic pulses with field strengths of approximately 1 
tesla and a pulse duration of 1 ms.  
 
Magnetic stimulation is achieved by [CONTACT_68268] 200 coil near 
neuromuscular tissues. Current flows from the instrument through the coil in one of two 
directions (depending on which side of the coil is facing the scalp). If side A is visible and side B 
is facing the site of stimulation, coil current flows in a counterclockwise direction and within the 
tissues current flows in a clockwise direction. If side B is visible and side A is facing the site of 
stimulation, coil current flows in a clockwise direction and within the tissues current flows in the 
counterclockwise direction. In the coil, current flows from positive to negative. Within tissues, 
current flow signifies the movement of ions.  
 
The Mayo Clinic Neurostimulation Laborat ory is equipped with two single -pulse magnetic 
stimulators (Magstim 200) and a bi -stim module for the delivery of paired magnetic stimuli at 
interstimulus intervals as short as [ADDRESS_74380] the motor evoked potential (MEP) for motor threshold 
determination. These bio -amplifiers are battery powered for AC isolation and customized to 
reduce artifact induced by [CONTACT_68269]. Features include low distortion and noise. They have 
especially rapid rate recovery after saturating signals. The amplified signals are digitized with 
Dell Dimension P200V (200 MHz) personal computers using analogic LS -DAS -12 A/Ds (250 
kHz). Computing facilities in the lab include a personal computer for the acquisition of 
electrophysiological data.  
 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
15 
 
Figure 1. Feasibility of 10 Hz 
rTMS for Adolescent Depression.  1.3 Preclinical Data  
 
Please see prior IDE applications G060269, G 110091, G120121 , present IDE application,  prior 
Study Determination (I111173), and all associated references.   
 
1.4 Clinical Data to Date  
 
Please see prior IDE applications G060269, G110091, G120121 , present application,  prior Study 
Determination (I111173),  and all associated references.  
  
Preliminary Studies: Our prior research with TMS measures of ICF53,[ADDRESS_74381] examined rTMS dose 
comparisons (1 Hz vs. 10 Hz) or explanatory biomarkers in the context of variable dosing.33,[ADDRESS_74382] studies  of 10 
Hz rTMS, at 120% motor threshold, applied to the left 
dorsolateral prefrontal cortex for 30 sessions over 6 
weeks.66,69  Initial results are encouraging in terms of 
feasibility and patient retention.  Primary clinical 
outcome measures with the clinician rated CDRS -R and 
secondary self -report measures with the 17 item Quick 
Inventory of Depressive Symptomatology Adolescent 
Version  Self-Report  (QIDS -A17-SR) demonstrated 
significant improvements throughout the 6 week 
treatments, posttreatment, and at a 6 month follow up 
visit (Figure 1). The durability of clinical effect at [ADDRESS_74383] simply examined adult dosing schedules of 10 Hz rTMS and 
are not informed by [CONTACT_68270] .  
 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
16 
 1.5 Study Rationale and Risk Analysis ( Risk s to Benefits  Ratio)  
1.5.1 Study Rationale  
 
Repetitive transcranial magnetic stimulation (rTMS) is a promising brain -based treatment for 
adolescent depression, but target engagement dosing strategies are not adequately understood.33 
A leading theory suggests that rTMS addresses pathological imbalances in cortical gamma -
aminobutyric acid (GABA) and glutamatergic tone.  There is a substantial knowledge gap 
regarding precision medicine approaches for dosing rTMS and the mechanisms associated with 1 
Hz and 10 Hz rTMS in adolescent depression.  Disruptions in excitatory and inhibitory 
neurotransmission are also implicated in negative valence and depression.  Anhedonia and early 
adversity are associated with poor outcomes in adolescent psychiatric disorders and may be 
linked to accentuated imbalances of cortical glutamatergic and GABAergic tone10,12,15,16, 71.  
Clarifying the mechanisms of rTMS for adolescent depression could catalyze intervention 
discovery for treatment resistant populations.47,52 
 
To solve these problems we propose a novel dose finding and target validation study of rTMS for 
adolesc ent depression with a biomarker -stratified , randomized  design. 72 Intracortical facilitation 
(ICF), 63 a transcranial magnetic stimulation (TMS) measure of cortical glutamatergic tone is the 
target engagement biomarker for the proposed trial.  A cohort of adolescents (ages 12 -18) with 
clinically significant depression defined as 40 or greater on the CDRS -R will be stratified 
according to baseline ICF (high defined as > 1.5 or low defined ≤ 1.5)26,28,[ADDRESS_74384] weekly 
ICF and CDRS -R measures during treatment. We will assess baseline anhedonia with a 
composite measure from relevant CDRS -R and Beck Depression Inventory -II (BDI -II) items. 
We will assess lifetime adversity with the Childhood Trauma Questionnaire (CTQ).  Depressed  
adolescent participants who do not respond to 1 Hz or 10 Hz rTMS will be offered the 
opportunity to participant in an exploratory, 2 week trial of iTBS or cTBS (novel dosing 
strategies of TMS therapy).  An ideal study would include a sham arm.  As noted there are 
substantial financial and pragmatic barriers to this in the proposed study.  Further, the proposed 
study is focused on developi[INVESTIGATOR_007] a mechanistic understanding of different doses of rTMS and the 
effectiveness of 1 Hz rTMS compared to 10 Hz as this has not been adequately addressed in 
previous work.  
 
Aim 1 examines the relative efficacy of 6 weeks low frequency (1 Hz) or high frequency (10 
Hz) left prefrontal rTMS according to a baseline ICF (ICF -15 % MEP amp)  measure of 
glutamatergic tone in depressed adolescents.  We will employ a biomarker stratified design.  
Depressed adolescents will be stratified by [CONTACT_68271] (≤ 1.5) or ICF high (>1.5) 
groups prior to randomization.  
• We expect that [ADDRESS_74385] greater efficacy (assessed by [CONTACT_68272] -R) in depressed adolescents with high baseline ICF compared to adolescents with low 
baseline ICF.  
• We expect that [ADDRESS_74386] greater efficacy (assessed by [CONTACT_68272] -R) in depressed adolescents with low baseline ICF compared to adolescents with high 
baseline ICF.  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
17 
 • [ADDRESS_74387] greater efficacy (assessed by [CONTACT_68273] -R) than 
6 weeks of 10 Hz rTMS in depressed adolescents with high baseline ICF.  
• [ADDRESS_74388] greater efficacy (assessed by [CONTACT_68273] -R) than 
6 weeks of 1 Hz rTMS in adolescents with low baseline ICF.  
 
Aim 2 examines changes in weekly ICF and CDRS -R across 6 weeks of either 1 Hz or 10 Hz 
rTMS.  
• We anticipate that ICF measures will decrease in depressed adolescents receiving 6 weeks of 1 
Hz rTMS.  
• We anticipate that ICF measures will increase in depressed adolescents receiving 6 weeks of 
10 Hz rTMS.  
• Depressive symptom improvement will have a direct relationship with ICF decrease in 
depressed adolescents receiving [ADDRESS_74389] relationship with ICF 
increase in depressed adolescents receiving 10 Hz rTMS.  
 
Exploratory Aim 3  
 
Aim 3a: To compare 7 T MRS cortical measures of GABAergic tone and glutamatergic 
neurochemistry in depressed adolescents and healthy control adolescents.  
 
Aim3b: To examine potential changes in cortical GABAergic and glutamatergic neurochemistry 
after a six week course of either 1 Hz or 10 Hz rTMS in depressed adolescents.  
 
Hypothesis:  
 
1. Depressed adolescents will have decreased cortical levels of GABA as assessed with [ADDRESS_74390]/Glu will decrease after [ADDRESS_74391]/Glu will increase after 6 weeks of 10 Hz rTMS in 
depressed adolescents.  
Exploratory Aim 4 examine s clinical moderators of treatment (anhedonia and adversity) in this 
sample of adolescents undergoin g treatment with 1 Hz and 10 Hz rTMS.  
 
Hypothesis:  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
18 
 6 weeks of low frequency (1 Hz) rTMS vs. high frequency (10 Hz) rTMS will have greater 
efficacy (as assessed by [CONTACT_68274] -R) in depressed adolescents with anhedonia and adversity 
compared to depressed adolescents without anhedonia and adversity  
 
The proposed project will examine an rTMS dosing, target engagement strategy for adolescent 
depression and refine understanding of GABAergic and glutamatergic contributions to negative 
valence.  Findings will inform the clinical dissemination of rTMS for adolescent depression and 
provide insights to further treatment innovation for disorders of the negative valence systems 
domain early in life.9,52 
 
To our knowledge the NeuroStar® TMS Therapy System in XPLOR research configuration  has 
been used most often in prior investigational studies of adolescent depression.33,69 Our group has 
existing and ongoing collaborations with Neuronetics  as documented in referenced IDE 
applications: G060269, G110091, G120121.  The present, proposed IDE application would 
deliver investigational, therapeutic TMS therapy (1 Hz, 10 Hz, cTBS, and iTBS) with the 
NeuroStar® TMS Therapy System in XPLOR research configuration . 
 
Although the interventional component of the study (randomized biomarker stratified trial of 1 
Hz or 10 Hz rTMS and extension trial of cTBS or iTBS) is considered more than minimal risk to 
adolescents, TMS treatments offer a potential direct benefit for the individual participant s.33,47  
Notably all depressed, adolescent participants will received an active form of TMS.  There is no 
placebo or sham condition.  In addition, the schedule of mood assessments and daily assessments 
during the interventional portion of the study for any adverse events has been developed for the 
purpose of monitoring the participants ’ well-being.  
 
All families and participants  for this study will be provided with a consent/assent form 
describing this study and providing sufficient information for Participant s to make an informed 
decision about their participation in this study.  This consent/assent form will be submitted with 
the protocol for review and approval by [CONTACT_68275]. The formal consent/assent of a 
participant,  using the approved IRB consent/assent form, must be obtained before that participant  
undergoes any study procedure.  This form must b e signed and dated by [CONTACT_68276]’s legally -authorized representative, and the individual obtaining informed 
consent/assent.  
 
1.5.[ADDRESS_74392] 
neurophysiologic data.  Therapeutic rTMS (1 Hz, 10 Hz, cTBS, and iTBS) applies multiple 
magnetic pulses to the brain over many (30 -40 in this protocol) sessions for treatment 
purposes.32,73 
 
Potential risk of seizure : There is a small risk of seizure associated with the use of TMS. This is 
regarded as the most serious adverse event ever reported in TMS studies to date. Seizures have 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74393] rTMS (1 Hz or 10 Hz).[ADDRESS_74394] risk. This incidence is still low (0.6% or less)  which is comparable to the reported 
incidence of seizures with antidepressant medications. .74,[ADDRESS_74395] been 17 case reports of 
seizures during TMS in healthy participants, depressed  participants , or participants with other 
disorders not thought to confer a seizure risk (such as pain).72 It is also noteworthy, that in a 
recent, multicenter trial of rTMS involving 301 adult patients receiving rTMS at 120% motor 
threshold, 3,000 pulses per session, five days a week for 4 -6 weeks (this is rTMS delivered at the 
upper limits of recommended safety guidelines) there were no seizures nor elevated rates of 
serious adverse events.[ADDRESS_74396] to the potential for seizures, all patients will be carefully screened for current or 
historical factors that may increase the risk of seizures (see Exclusion criteria). The Transcranial 
Magnetic Stimulation Adult Safety Screen (TASS) will be used to specifically query for any 
potential seizure risks. Neurologic disease which may increase the risk for seizures is part of the 
exclusion  criteria.74,[ADDRESS_74397] access (within minutes) to emergency medicine services.  
 
In the event of a seizure, the supervising physician  will initiate appropriate clinical care as 
defined within the clinical rTMS practice.  In the management of seizures, attention must be 
taken to minimize the risk of aspi[INVESTIGATOR_1516], and when possible guiding the patient into the left lateral 
decubitus position is d esirable.  Because seizures in the context of TMS  are brief (typi[INVESTIGATOR_897] <60 
seconds) and without serious physical sequelae, efforts will be focused on preventing 
complications of the seizure rather than initiating any specific medication that is not required 
unless a seizure is prolonged.  If a prolonged seizure (>60 seconds) is identified, appropriate 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
20 
 response measures will be initiated which may include notifying a hospi[INVESTIGATOR_307] -based pediatric  rapid 
response team and/or escorting participant  to the emergency  medicine  department upon 
stabilization (located directly across  from TMS building ).  The patient may be provided 
lorazepam (or equivalent benzodiazepi[INVESTIGATOR_68237]) to abort the seizure.  
To date, status epi[INVESTIGATOR_68238].47,74,[ADDRESS_74398] ( DSM B), Neuronetics , and the FDA as required per agreements, regulati ons, and policies . 
 
Neuropsychological function after TMS : Several studies have examined the short -term effects 
of rTMS administration across a range of stimulation parameters, and found little or no evidence 
to suggest a change in cognitive function as a result of rTMS administration.66,74,[ADDRESS_74399] neurocognitive data at baseline, posttreatment  (Phase I 
and Phase II) , and at a [ADDRESS_74400],   PhD will oversee the implementation, training, 
administration, quality assurance, and data analyses of neurocognitive testing (NIH Toolbox)  
 
Potential risk of alteration of auditory threshold : During TMS, the coil produces an audible, 
high energy click. Existing evidence suggests that TMS can result in transient changes in 
auditory threshold if no precautions are taken (such as wearing earplugs during TMS).  Ear plugs 
are required for all participants and study personnel during any TMS procedure.  These are worn 
routinely during TMS protocols to mitigate this risk.38,74  Participants will undergo audiometry 
testing at baseline and upon completion of 6 week rTMS (1 Hz or 10 Hz) and once again (if 
applicable ) after the two week trial (of either cTBS or iTBS).  
 
Potential for unintended behavioral change: (e.g., worsening of depression or induction of 
mania): Crying has been reported in some patients receiving left prefrontal rTMS. There is no 
evidence to suggest that a frank worsening of depression may be seen in patients with major 
depression receiving rTMS. On the other hand, mania has been observed in bipolar disorder 
patients who have received rTMS.38,74,[ADDRESS_74401] will remain in the neurostimulation suite (in a room adjacent to the 
rTMS treatment room) during all rTMS treatment sessions .   
 
Suspected treatment -induced mania will be evaluated using the Young Mania Rating Scale 
(YMRS).  A YMRS score of ≥ 20 will prompt administration of the M.I.N.I. (age 18) or M.I.N.I. 
KID to determine whether or not the Participant  meets the Diagnostic and Statistical Manual of 
Mental Disorders, Fifth Edition (DSM -5) criteria for mania.  A YMRS score of 20 or greater will 
be considered an adverse event (AE) and will be monitored using the YMRS; the emergence of 
DSM -5 verified mania will be treated as a serious adverse event (SAE) and will also be 
monitored using the YMRS.   
 

Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74402] Certified Child and Adolescent 
Psychiatrists with expertise in adolescent depression, suicidality, severe psychiatric disorders in 
childhood, rTMS protocols, and clinical research. These psychiatrists are co -investigators and 
colleagues.  One of these physicians (in the event [CONTACT_68314] is away) or [CONTACT_68314] is 
present in the treatment suite during rTMS delivery and available [ADDRESS_74403] 
experience implementing.   For example, this team collectively has had experience in 
hospi[INVESTIGATOR_68239]. The overriding guiding principal for our research team is that 
participant  safety is our central priority.  Any decisions regarding clinical monitoring, referral for 
higher levels of treatment, and ongoing study participation are informed by [CONTACT_68277] ’s safety and clinical status.   Beyond this, the Mayo Clinic Division of Child and 
Adolescent Psychiatry ([ADDRESS_74404] certified child and adolescent psychiatrists) always has an 
individual on call for psychiatric emergencies. While these colleagues are not co -investigators, 
they receive training on a regular basis regarding ongoing adolescent research efforts.  All 
members of the Child and Adolescent Psychiatry Division have proficiency and comfort in 
dealing with psychiatric emergencies. They contact [CONTACT_978] ([CONTACT_68314]) or the covering 
research child and adolescent psychiatrist with any emergency involving a research participant.  
Research participants are ultimately offered standard of care interventions based on clinical 
presentation and need regardless of stage of participation (to include emergent evaluation in 
outpatient clinic, emergency medicine visits, or psychiatric hospi[INVESTIGATOR_68240], 
Generose [ADDRESS_74405], an 18 bed inpatient unit which is located directly below our neurostimulation 
treatment suite).  
 
Potential risk of movement of metallic objects in the patient’s body: Because of the brief, but 
intense local magnetic field induced by [CONTACT_68278], any metallic object in the vicinity of the 
coil, namely within the head region, may slightly move as a result. Patients with metallic objects 
in or near their head are excluded from the study. Patients will be specifically instructed to 
remove any magnetically sensitive jewelry or other objects near  their head.   Patients with 
metallic objects in or near their head are excluded from the study. Patients will be specifically 
instructed to remove any magnetically sensitive jewelry or other objects near their head.38,74,75 
 
Potential for development of headache or local pain at the site of stimulation: TMS 
administration may result in the development of a transient headache during or after the TMS 
session, and the development of pain localized near the site of the stimulation coil. These effects 
are thought to be due to the direct activation of muscles and nerves near the stimulating coil.  This 
is more common with rTMS and  TBS than with single or paired -pulse  TMS. TMS sessions or 
measurements will be discontinued immediately in the event of any signi ficant scalp discomfort 
or pain.  Participants will be counseled on the use of ibuprofen to relieve pain or discomfort as 
necessary .38,74,75 
 
Unimproved depression or Clinical Deterioration: Continued depression or worsening of 
depressive symptomatology is always a risk of depression , even for those treated with 
medication and/or psychotherapy.  Clinical deterioration due to the underlying psychiatric 
conditions is also a risk. The PI ([CONTACT_68314]) is a board -certified child and adolescent 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74406]. Croarkin (or a child and adolescent psychiatrist research 
team member ) will follow standard policies and procedures developed by [CONTACT_68279]. The study 
psychiatris t will implement strategies to ensure each partcipant ’s safety and optimal clinical 
outcome (e.g., comprehensive assessment of depressive symptomatology including possible 
lethality, immediate notification to the adolescent participant ’s legal guardian, and referral to 
community treatment providers). Implementation of strategies to mitigate worsening of 
depression will be tailored to the specific needs of the individual.  
 
During the consent process, participants  and families will be educated about the possibility of 
significant changes in mood, suicidal thinking, and/or behaviors during the treatment.  These 
changes could include emergence of mania, worsening of depression, and/or suicidal thinking 
and behaviors. Both the participants  and parent(s) will be told to initiate contact [CONTACT_68280], if the participant e xperience s any significant mood or behavior changes including 
suicidal ideation.  Principal Investigator [INVESTIGATOR_68241]/assent 
document.  Furthermore, during the treatment phases of the  study,  participants will have frequent 
contact [CONTACT_9881] (5 visits per week) and assessments weekly where changes of 
psychological symptoms will be queried .  Ongoing monitoring for worsening of depression and 
emergence of suicidal ideation and/or behaviors will be evaluated using the CDRS -R, C-SSRS, 
and clinical global impression -severity scale ( CGI-S). 
 
Suicidal behavior : Patients with current suicidal ideation or past suicide attempts are eligible for 
the study (unless outpatient treatment is not clinically indicated), as ongoing suicidal ideation 
and behaviors are frequently seen in depressed youth. Therefore, ongoing suicidal ideation or 
worsening of suicidal ideation and behavior is a risk . The PI ([CONTACT_68314]) is a board -certified 
child and adolescent psychiatrist with extensive experience treating adolescents with suicidal 
behavior.  The research team includes three other board certified chi ld and adolescent 
psychiatrists.  [CONTACT_68314] or the research child and adolescent psychiatrist will follow standard 
policies and procedures developed by [CONTACT_68281] C hild and Adolescent Division and 
implement strategies (e.g., comprehensive assessment of depressive symptomatology, 
assessment of suicidal ideation [inclusive of intent, means, and plan], immediate notification of 
the adolescent participan ts’ legal guardian, referral for admission to Generose, [ADDRESS_74407], the Mayo 
Clinic Child and Adoles cent Inpatient Psychiatry unit [ in cases of immediate lethality ]). 
Implementation of strategies to mitigate suicidal behavior will be tailored to the specific 
presenting needs of the individual.  
 
Please note that [CONTACT_68314] works with a team of Board Certified Child and Adolescent 
Psychiatrists with expertise in adolescent depression, suicidality, severe psychiatric disorders in 
childhood, rTMS p rotocols, and clinical research.  These psychiatr ists are co -investigators and 
colleagues.  One of these physicians (in the event [CONTACT_68314] is away) or [CONTACT_68314] is 
present in the treatment suite during rTMS delivery and available [ADDRESS_74408] operating  procedures that the team of psychiatrists are 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74409] experience implementing.  For example, this team collectively has 
had experience in hospi[INVESTIGATOR_68242]. The overriding guiding principal 
for our research team is that participant  safety is our central priority.  Any decisions regarding 
clinical monitoring, referral for higher levels of treatment, and ongoing study participation are 
informed by [CONTACT_68282] ’s safety and clinical status.   Beyond this, the 
Mayo Clinic Division of Child and Adolescent Psychiatry ([ADDRESS_74410] certified child and 
adolescent psychiatrists) always has an individual on call for psychiatric emergencies. While 
these colleagues are not co -investigators, they receive training on a regular basis regarding 
ongoing adolescent research efforts.  All members of the Child and Adolescent Psychiatry 
Division have proficiency and comfort in dealing with psychiatric emergencies. They contact [CONTACT_1600] ([CONTACT_68314]) or the covering research child and adolescent psychiatrist with any emergency 
involving a research participant.  Research participants are ultimately offered standard of care 
interventions based on clinical presentation and need regardless of stage of participation (to 
include emergent evaluation in outpatient clinic, emergency medicine visits, or psychiatric 
hospi[INVESTIGATOR_68240], Generose [ADDRESS_74411], an 18 bed inpatient unit which is located 
directly below our neurostimulation treatment suite).   
 
MRI/MRS Safety Concerns in Humans  
 
Potential Risks  
 
The effects of magnetic fields in an MRI scanner have been extensively studied, and there are no 
known significant risks with an MRI exam. Some subjects may be bothered by [CONTACT_68283] (claustrophobia), and by [CONTACT_68284]. 
Subjects will wear earplugs while in the magnet. Subjects with pacemakers, implanted 
defibrillators or other implanted electronic or metallic devices may not participate. Subjects with 
braces may not participate in the MRI/MRS scan portion of the study.   
 
Clinical Assessments and Neurocognitive Testing with NIH Toolbox  
 
The psychiatric assessment, interview, and rating scales in this study are time consuming and 
may bring up upsetting issues. If child abuse is detected, the research team is obligated to follow 
mandatory, federal, state, and institutional reporting laws.  On occasion participants clinically 
deteriorate during a research assessment.  [CONTACT_68314] or a board -certified child and adolescent 
psychiatrist from the research team will be available [ADDRESS_74412], , PhD will oversee the 
implementation, training, administration, quality assurance, and data analyses of neurocognitive 
testing (NIH Toolbox)  
 
Confidentiality  
 
The potential for a breach in confidentiality always exists, specifically with the written research 
data and study databases. However, information that is obtained will be stored in locked file 
drawers in locked offices; data will have identifying information sheered from it to prevent loss 
of confidentiality, all computers and databases will be password protected with passwords 
available to limited study personnel, and all staff must sign confidentiality certificates.   

Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74413] is to decline.  Participants will be at no risk if they decline to participate . 
 
1.5.3  Potential Benefits  
 
Although the interventional component of the study (randomized biomarker stratified trial of 1 
Hz or 10 Hz rTMS and extension trial of cTBS or iTBS  for nonresponders ) is considered more 
than minimal risk to adolescents, TMS treatments offer a potential direct benefit for the 
individual participant.33 81,82 Notably all depressed, adolescent participants will received an 
active form of TMS.  There is no placebo or sham condition.  In addition, the schedule of mood 
assessments and daily assessments during the interventional portion of the study for any adverse 
events has been developed to optimize monitoring the participant ’s well -being.  
 
Standard TMS dosing  (1 Hz and 10 Hz) ha s been applied more broadly  than TBS  to children and 
adolescents in the course of investigational, therapeutic studies.[ADDRESS_74414] stimulati on (iTBS) and continuous theta -burst (cTBS) exploratory 
extension  trial (Phase II of the proposed study)  is to maximize the infrastructure of the proposal 
for both research participants  and our field.  Theta burst stimulation (TBS) is an alternative 
dosing approach in which [ADDRESS_74415] stimulation (cTBS) 
delivers [ADDRESS_74416] focused on neurostimulation the PI/sponsor  
has taken every opportunity to interact with national and international clinical communities that 
focus on the deli very of TMS  therapi[INVESTIGATOR_014] .  This has included volunteering for the Clinical TMS 
Society Board of Directors, attending International Brain Stimulation conferences, and visiting 
multiple national and international TMS clinics and laboratories.  From these experiences it is 
clear that TBS protocols are increasi ngly delivered in clinical settings to adults and adolescents 
despi[INVESTIGATOR_040] a relatively underdeveloped understanding of the in vivo neurophysiological effects in 
humans. This is particularly concerning in the context of developi[INVESTIGATOR_68243] . Systematic study 
and data collection  (efficacy measures, safety, adverse events, and neurophysiological data)  
focused on TBS is critical in this context. Based on prior experience of the PI, research 
participants  (and their parents)  who do not receive benefit from the propose d, primary, 
experimental therapeutic protocol ( Phase I: 6 weeks of either 1 Hz or 10 Hz rTMS) would 
appreciate the availability of an additional treatment protocol with an experienced center in 
which safety is maximized.  Practically, an extension trial of TBS would also present an 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74417] novel pi[INVESTIGATOR_42101] 
(Exploratory Clinical Trials of Novel Interventions for Mental Disorders R61/R33).8  
 
1.6 Anticipated Duration of the Clinical Investigation  
 
It is anticipated that the proposed study will be five years in duration.  For individual 
participants, Phase I (biomarker stratified, randomized trial of 1 Hz vs. 10 Hz rTMS) is 10 we eks 
in duration.  Phase II ( trial of cTBS vs iTBS based on ICF biomarker status) is 3 weeks in 
duration.  
 
2 Study Objectives  
 
The proposed study is a dose finding , effectiveness,  and target validation study of rTMS for 
adolescent depression with a biomarker stratified design. 72 Intracortical facilitation (ICF), 65 a 
transcranial magnetic stimulation (TMS) measure of cortical glutamatergic tone is the target 
engagement biomarker for the proposed trial.  In phase I, a  cohort of adolescents (ages 12 -18) 
with clinically significant depression defined as 40 or greater on the Children’s Depression 
Rating Scale -Revised (CDRS -R) will be stratified according to baseline ICF (high defined as > 
1.5 or low defined ≤ 1.5) and then randomized to [ADDRESS_74418] weekly ICF and CDRS -R measures during treatment. We 
will assess baseline anhedonia with a composite measure from relevant CDRS -R and Beck 
Depression Inventory -II (BDI -II) items. We will assess lifetime adversity with the Childhood 
Trauma Questionnaire (CTQ).  
 
Participants in Phase I will be offered the opportunity to have 3 and 7 T MRI and MRS looking 
for biomarkers at baseline and after 6 weeks of treatment.  A subgroup of depressed adolescent 
participants ( up to 50) who do not respond to 1 Hz or 10 Hz rTMS will be offered the 
opportunity to participant in an exploratory, 2 week, trial of iTBS or cTBS based on ICF 
biomarker status  (Phase II of the study) .  Participants with high baseline ICF ( defined as > 1.5 ) 
will be assigned to cTBS treatment.  Participants with low ICF  (defined ≤ 1.5)  will be assigned 
to iTBS.  
 
[ADDRESS_74419] of 1 Hz and 10 Hz rTMS on cortical glutamate 
and GABA neurochemical markers  when compared to the healthy adolescent cohort.  
 
2.1 Primary Objective  
 
Aim 1  examines the relative efficacy of 6 weeks low frequency (1 Hz) or high frequency (10 Hz) 
left prefrontal rTMS according to a baseline ICF (ICF -15 % MEP amp)  measure of 
glutamatergic tone in depressed adolescents.  We will employ a biomarker stratified design.  
Depressed adolescents will be stratified by [CONTACT_68271] (≤ 1.5) or ICF high (>1.5) groups 
prior to randomization.  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
26 
 • We expect that [ADDRESS_74420] greater efficacy (assessed by [CONTACT_68272] -R) in depressed adolescents with high baseline ICF compared to adolescents with low 
baseline ICF.  
• We expect that [ADDRESS_74421] greater efficacy (assessed by [CONTACT_68272] -R) in depressed adolescents with low baseline ICF compared to adolescents with high 
baseline ICF.  
• [ADDRESS_74422] greater efficacy (assessed by [CONTACT_68273] -R) than 
6 weeks of 10 Hz rTMS in depressed adolescents with high baseline ICF.  
• [ADDRESS_74423] greater efficacy (assessed by [CONTACT_68273] -R) than 
6 weeks of 1 Hz rTMS in adolescents with low baseline ICF.  
 
2.2 Secondary Objective  
 
Aim 2 examines changes in weekly ICF and CDRS -R across 6 weeks of either 1 Hz or 10 Hz 
rTMS.  
• We anticipate that ICF measures will decrease in depressed adolescents receiving 6 weeks of 1 
Hz rTMS.  
• We anticipate that ICF measures will increase in depressed adolescents receiving [ADDRESS_74424] relationship with ICF increase in 
depressed adolescents receiving 10 Hz rTMS.  
Exploratory Aim 3  
 
Aim 3a: To compare 7 T MRS cortical measures of GABAergic tone and glutamatergic 
neurochemistry in depressed adolescents and healthy control adolescents.  
 
Aim3b: To examine potential changes in cortical GABAergic and glutamatergic neurochemistry 
after a six week  course of either 1 Hz or 10 Hz rTMS in depressed adolescents.  
 
Hypothesis:  
 
1. Depressed adolescents will have decreased cortical levels of GABA as assessed with [ADDRESS_74425]/Glu will decrease after 6 weeks of 1 Hz rTMS in 
depressed adolescents.  
 
5. Bilateral cortical 7 T MRS measures of GABA will decrease after 6 weeks of 10 Hz rTMS in 
depressed adolescents.  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74426]/Glu will increase after 6 weeks of 10 Hz rTMS in 
depressed adolescents.  
 
Exploratory Aim  4 examine s clinical moderators of treatment (anhedonia and adversity) in this 
sample of adolescents undergoin g treatment with 1 Hz and 10 Hz rTMS.  
 
Hypothesis:  
6 weeks of low frequency (1 Hz) rTMS vs. high frequency (10 Hz) rTMS will have greater 
efficacy (as assessed by [CONTACT_68274] -R) in depressed adolescents with anhedonia and adversity 
compared to depressed adolescents without anhedonia and adversity  
 
The proposed project will examine an rTMS dosing, target engagement strategy for adolescent 
depression and refine understanding of GABAergic and glutamatergic contributions to negative 
valence.  Findings will inform the clinical dissemination of rTMS for adolescent depression and 
provide insights to further treatment innovation for disorders of the negative valence systems 
domain early in life.9,52 
 
To our knowledge the NeuroStar® TMS Therapy System in XPLOR research configuration  has 
been used most often in prior investigational studies of adolescent depression.33,69 Our group has 
existing and ongoing collaborations with Neuronetics  as documented in referenced IDE 
applications: G060269, G110091, G120121.  The present, proposed IDE application would 
deliver investigational, therapeutic TMS therapy (1 Hz, 10 Hz, cTBS, and iTBS) with the 
NeuroStar® TMS Therapy System in XPLOR research configuration . 
 
Although the interventional component of the study (randomized biomarker stratified trial of 1 
Hz or 10 Hz rTMS and extension trial of cTBS or iTBS) is considered more than minimal risk to 
adolescents, TMS treatments offer a potential direct benefit for the individual participant s.33,47  
Notably all depressed, adolescent participants will received an active form of TMS.  There is no 
placebo or sham condition.  In addition, the schedule of mood assessments and daily assessments 
during the interventional portion of the study for any adverse events has been developed for the 
purpose of monitoring the participants’ well-being.  
 
All families and participants  for this study will be provided with a consent/assent form 
describing this study and providing sufficient information for Participant s to make an informed 
decision about their participation in this study.  This consent/assent form will be submitted with 
the protocol for review and approval by [CONTACT_68275]. The formal consent/assent of a 
participant,  using the approved IRB consent/assent form, must be obtained before that participant  
undergoes any study procedure.  This form must b e signed and dated by [CONTACT_68276]’s legally -authorized representative, and the individual obtaining informed 
consent/assent.  
 
3 Study Design  
3.1 General Design  
 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
28 
  
 
 
 
Phase I will enroll a cohort (N= 120) of adolescents (ages 12 -18) with clinically significant 
depression defined as 40 or greater on the Children’s Depressio n Rating Scale -Revised (CDRS -
R).  Participants will be stratified according to baseline ICF (high defined as > 1.5 or low defined 
≤ 1.5) and then randomized to [ADDRESS_74427] weekly ICF and CDRS -R measures during treatment. We will assess 
baseline anhedonia with a composite measure from relevant CDRS -R and Beck Depression 
Inventory -II (BDI -II) items. We will assess lifetime adversity with the Childhood Trauma 
Questionnaire (CTQ).  Participants will have baseline neurocognitive testing.  Participants will 
have a six month follow -up visit with depression severity measures (CDRS -R and BDI -II) and 
neurocognitive assessments.  
 
Up to 100 Depressed  adolescents  will be offered the opportunity to undergo  magnetic resonance 
spectroscopy (MRS) measure at baseline (prior to any Phase I TMS treatment)  and posttreatment 
visits (within 2 months after 6 weeks of TMS treatment  in Phase I ).  A comparison group of 30 
healthy control adolescents will be offered the opportunity to undergo MRS at one time point. A 
subset of up to 50 depressed adolescents who do not respond to Phase I TMS treatment will be 
offered the opportunity to continue in Phase II (within 2 months of completion of Phase I 
treatment) for two weeks of either iTBS if (ICF ≤ 1.5  ) or cTBS if (ICF is >1.5).  

Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
29 
 . 
 
Magnetic Resonance Imaging:  Depressed and control participants will undergo 3 T structural 
MRI and ultra -high field (7 T) MRS (7 -T, 90 –cm horizontal bore magnet interfaced with a 
Siemens console) to examine GABA, glutamate, and glutamine concentrations in the occipi[INVESTIGATOR_68244] (OCC)   [CONTACT_68315] is a co -investigator on this grant and will supervise the 
collection and analyses of all MRI/MRS data at the Center for Magnetic Resonance Research 
(CMRR) at the University of Minnesota.  Please note that travel time from Mayo Clinic 
[COMPANY_002]ster to the CMRR is approximately 1 hour.  Participants will be remunerated for travel and 
all study visits.  
 
 Recent work in adult humans with 7 T MRS and short echo time sequences has enhanced the 
detection and resolution of GABA, glutamate and glutamine. Spectra will be acquired from a 
voxel   placed in the OCC  using the STEAM sequence. Voxels will be prescribed using 
anatomical landmarks from T1 -weighted images. Spectra will be stored separately for 
subsequent automatic frequency and phase correction (in -house written Matlab routines) using 
the NAA signal at 2.01 ppm. Summed spectra will be analyzed using LCModel 6.1 -4A (Stephen 
Provencher Inc., Oakville, ON, Canada) and simulated basis sets with a metabolite -nulled 
macromolecule spectrum measured in vivo .. No baseline correction, zero -filling or apodization 
functions will be applied to the in vivo data prior to the analysis. LCModel fitting will be 
performed over the spectral range from 0.5 to 4.2 ppm. The quantification will be performed 
using the unsuppressed water signal obtained from the same voxel. Concentrations will be 
corrected for cerebrospi[INVESTIGATOR_68245] (the tissue composition will be obtained vial voxel 
segmentation using T1 -weighted images acquired at 3 T).   
 
The first MRS will take place following the screening visit but before the baseline/treatment visit 
occurs . Therefore, a [ADDRESS_74428]  within 2 months of  completing all rTMS phase I treatments  and 
assessments and before beginning Phase 2  treatments . Screening will include  University of 
Minnesota Center for Magnetic Resonance Research  systematic safety assessments for safety to 
undergo both rTMS and ultra -high field (7 T) MRI/MRS.   
 
Please note that travel time from Mayo Clinic [COMPANY_002]ster to the CMRR is approximately 1 hour.  
Participants will be remunerated $100.00 per scan for their time and travel expenses.  
 
Research participants: We will enroll participants ages 12 to 18 with the capacity to provide 
informed assent and parents (for participants younger than age 18) with the capacity to provide 
informed consent.  Capacity to consent will be assessed with comprehension assessments.  We 
are budgeted  to recruit 120 depressed adolescents over five years for a target of 100 evaluable 
subjects (120 accounts for attrition based on our prior experience).   We are budgeted to recruit 
[ADDRESS_74429] studies.  These goals are 
realistic given our group’s experience with therapeutic rTMS and biomarker studies.  Screening 
will include systematic safety assessments for safety to undergo both rTMS and ultra -high field 
(7 T) MRI/MRS.   
 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
30 
 Participants who fail to receive clinical benefit from Phase I (defined as a CDRS -R score of [ADDRESS_74430] -treatment) will be offered enrollment i n Phase II (N=50 max).  The decision to 
enroll in Phase II can be made by [CONTACT_68285] [ADDRESS_74431] day of Taper 
Week 3.  During phase II, participants will be assigned to 2 weeks of cTBS if their intracortical 
facilitation measure (baseline assessment for TBS extension trial) is >1.5 (building on the current 
speculation that cTBS would be expected to decrease cortical excitability and ICF measures).  
Participants will be assigned to 2 weeks of iTBS if their ICF (baseline assessment for TBS 
extension trial) is < 1.5 (building on current speculation that iTBS would increase cortical 
excitability and ICF measures.  All participants in Phase II will have a six month follow -up visit 
with depression severity measures (CDRS -R and BDI -II) and neurocognitive assessments .   
 
3.2 Primary Study Endpoint s 
 
The primary study endpoint is depression severity (measured by [CONTACT_68274] -R total) over the 6 -week 
study period .   
 
3.3     Secondary Study Endpoints . 
 
The secondary study endpoint is i ntracortical facilitation (ICF) over the 6 -week study period.  
 
 
  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
31 
 3.4 Table 1 Primary Safety Endpoints  
 
 
Assessment  Description  
Adverse events  Participants  will be evaluated for adverse events at each visit. Serious 
adverse events (SAEs) will be reported as they occur to the Mayo 
Clinic IRB and [LOCATION_003] FDA (as per regulations). Systematic data 
collection focused on adverse events will include the Pediatric 
Adverse Event Rating Scale and Physical Symptom Checklist. These 
rating scales will be administered at baseline, weekly (during all 
rTMS, c TBS, and iTBS treatment weeks), at the 6 month follow up 
visit, and at study exit.  
Auditory thresholds  Participants  will undergo audiometry testing at baseline and upon 
completion of 6 week rTMS (1 Hz or 10 Hz) and once again (if 
applicable) after the two week open extension trial (of either cTBS or 
iTBS).  
C-SSRS – Columbia Suicide 
Severity Rating Scale  This is collected to assess lifetime suicidal ideation and behavior prior 
to participation, reassessed weekly (during 6 week trial of 1 Hz vs 10 
Hz rTMS and if applicable 2 week extension trial of cTBS or iTBS) 
during treatments, posttreatment, and 6 month follow up visit.  
NIH Toolbox Co gnition  Battery  http://www.healthmeasures.net/explore -measurement -systems/nih -
toolbox  
 
Cognition measures: http://www.healthmeasures.net/explore -
measurement -systems/nih -toolbox/intro -to-nih-toolbox/cognition  
 
The NIH Toolbox Cognition Battery , recommended for ages 7+, 
consists of tests of multiple constructs. It yields individual measure 
scores and the following summary scores:   Education, Handedness, 
Attention (Flanker Inhibitory Control and Attention Test),  Epi[INVESTIGATOR_6368] (Pi[INVESTIGATOR_17121], and Auditory Verbal 
Learning Test), Executive Function (Dimensional Change Card Sort 
Test, Flanker Inhibitory Control and Attention Test), Language 
(Pi[INVESTIGATOR_17122], Oral Reading Recognition Test), Processing 
Speed (Pattern Comparison Processing Speed Test), Working Memory 
(List Sorting Working Memory Test).  Collected at baseline, 
posttreatment, and 6 month follow up.  
 
Pediatric Adverse Event Rating 
Scale  This is a 51 item; self -report measure collected at baseline, weekly 
during rTMS treatments, posttreatment, and at [ADDRESS_74432]  This is a 46 item  measure to be collected by [CONTACT_3476] (under the 
supervision of the PI) at baseline, weekly during rTMS treatments, 
posttreatment, and at 6 month follow up visit for adverse event 
monitoring.  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
32 
 Assessment  Description  
Vital Signs  (Pulse, blood pressure, height, and weight) will be collected at 
baseline, upon completion of 6 week rTMS (1 Hz or 10 Hz) once 
again (if applicable) after two week open extension trial (of either 
cTBS or iTBS), and at 6 month follow up visit.  
YMRS -Young Mania Rating        
Scale  This is an 11 item measure used to assess for manic symptoms.  The 
YMRS scale will be completed at baseline and repeated during the 
course of study participation if symptoms of mania occur in a study 
participant.  If the YMRS is positive, A MINI/MINI -Kid will be 
repeated to evaluate for mania.  If the study participant meets full 
DSM -5 criteria for mania or hypomania he or she will be discontinued 
from the study and followed clinically.  
 
4 Participant Selection , Enrollment  and Withdrawal  
 
4.1 Inclusion Criteria  
 
Inclusion Criteria:  
- ages [ADDRESS_74433] a primary diagnos is of MDD based on a clinical and 
structured interview with the MINI  
-Depression symptoms severity of a 40 or greater based on evaluation with the Children’s 
Depression Rating Scale Revised (CDRS -R) at screening and baseline visits. Further, the total 
score of the baseline CDRS -R score must not have had a 25% or greater decrease from the 
screening CDRS -R score  
-The duration of the current epi[INVESTIGATOR_68246] [ADDRESS_74434] 1 week prio r (4 weeks for fluoxetine) to the baseline visit.  
-Participants in psychotherapy are eligible provided that this was initiated 4 weeks prior to 
enrollment and that the frequency of visits will be maintained during study participation.  
4.1.1   Inclusion Criteria Healthy Controls  
-ages 12 -18, male or female  
4.2 Exclusion Criteria  
Exclusion Criteria:  
-The following psychiatric comorbidities are exclusionary: psychotic disorders, bipolar 
disorders, anorexia nervosa, bulimia nervosa, and substance use disorders within the past year 
(with the exception of caffeine and tobacco)  
-A positive urine drug screen at baseline    
-Seizure history  
-Family history of epi[INVESTIGATOR_58824] a first degree relative  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
33 
 -Head trauma with loss of consciousness for greater than 5 minutes  
-Any true positive finding s on the rTMS safety screening form . 
- Contraindications to MRI/MRS  (CMRR Subject Safety Screening Form)  
-Any concurrent psychotropic medications (for potential participants  receiving antidepressants or 
psychotropic medications, the referring clinician must determine that insufficient benefit is being 
received from the treatment and if clinically appropriate, discontinue existing antidepressants and 
other psychotropic medications) . 
-Prohibited concomitant medications (See Appendix A) 
-Pregnancy or suspected pregnancy in female Participant s (assessed with urine pregnancy test)   
- Conductive, ferromagnetic, or other magnetic -sensitive metals implanted in the subject’s head 
within 30 cm of the treatment coil excluding the mouth that cannot safely be removed. Examples 
include cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils, stents, 
bullet fragments, jewelry and hair barrettes.  
-Prior brain surgery  
-Risk for increased intracranial pressure such as a brain tumor  
-Any unstable medical condition  
-History of treatment with ECT or TMS Therapy for any disorder  
-Use of any investigational drug within [ADDRESS_74435] 4 weeks  
-Suicide attempt within the previous 6 months that required medical treat ment or ≥ 2 attempts in 
the pas t 12 months, or has a clear cut plan for suicide and states that he/she cannot guarantee that 
he/she will inform a family member or call his/her psychiatrist or the investigator if the impulse 
to implement the plan becomes substantial during the study; or, in the investigator's opi[INVESTIGATOR_1649], is 
likely to attempt suicide within the next 6 months.  
4.2.2 Exclusion Criteria Healthy Controls  
-History of depression or any psychiatric treatment  
-Subjects found to be pregnant at time of screening will be ineligible  
-Positive urine drug screening  
-Contraindications to MRI/MRS  (CMRR Subject Safety Screening Form)  
4.[ADDRESS_74436]. Croarkin directs a research program and outpatient clinic for adolescent mood 
disorders. Our group historically has been successful in the recruitment of similar samples.   
 
Additional resources will be utilized for recruitment of potential participants including:  
• from within the clinical and referral practices of  the clinical study site  
• referrals from other care providers within the treatment communities  
• radio advertisements  
• invitation letters sent to parents of potentially eligible participant s 
• print advertisements, including but not limited to brochures, flyers, and listings in research 
classifieds  
• trial listing with ClinicalTrials.gov  
• trial listing on university and clinical study site website  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
34 
 • social media  
 
All advertising materials will be reviewed and approved by [CONTACT_68286].  
 
Potentially interested adolescents and their families may be provided with printed participant 
educational materials to aid them in making an informed decision regarding their willingness to 
participate in this study. In addition, parents of potentially eligible patients identified via i2b2 
search will be contact[CONTACT_68287] -approved email and follow -up telephone call s if necessary.  
 
Institutional Review Board (IRB) approval will be obtained for the consent and assent form.  The 
investigators will describe the study in full and complete a series of written comprehension 
questions to verify an understanding of the discomforts and potential bene fits to the study. 
Participants and parents will then be asked to sign the consent and assent forms prior to 
participation.  [CONTACT_68314] or a research team member that [CONTACT_68314] has trained and 
supervises will explain the details of the study, answer any study related questions, and obtain 
informed assent and consent from the participants and their parents or legal guardians.  [CONTACT_68316] or a board -certified child and adolescent psychiatrist will be available [ADDRESS_74437] clinical care 
or appropriate referrals (based on patient preference) to patients who exit the study or complete 
all study procedures . 
 
After providing informed consent and assent, participants will undergo an initial clinical 
assessment with a structured diagnostic interview (MINI), urine drug screen, safety screens, 
symptom rating scales, and a neurocognitive battery with the NIH tool box.86  Participants will 
then undergo TMS neurophysiology testing to generate a baseline ICF (interstimulus interval of 
15 milliseconds) measure for the purpose of stratification.  Baseline visits study procedures can 
be performed on the same date at Screening visit procedures or over 2 -3 separate visits based on 
Participant  preference and comfort.  Upon completion of baseline measurements and procedures, 
participants will be randomized to 1 Hz or 10 Hz rTMS.   
 
Preventing participant attrition during investigational, therapeutic TMS:  Treatment 
sessions are delivered 5 days per week consistent with prior systematic research.33,47,8 3, 38 We 
will offer treatment sessions on the weekend (for a total of 5 weekly sessions) when necessary to 
accommodate the participant scheduling constraints over a period of [ADDRESS_74438] 
week of rTMS treatment intensity may be adjusted for participant comfort to a minimum of 80% 
motor threshold and titrated by 10% daily to 120% of resting motor threshold.  We have found 
that these scheduling and titration procedures are highly effective for retaining adolescent 
participants for investigational therapeutic rTMS  
 
It is anticipated that 150 participants will be screened to enroll 120 participants for Phase I.  A 
maximum of 50 participants will be enrolled in Phase II.   Prior clinical experience and research 
with 10 Hz and 1 Hz rTMS suggests that approximately 50% of Phase I participants (N=60) will 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74439] rTMS approaches. Based on prior work it is unlikely that no more than 50 
participants will be eligible and interested in enrollment in Phase II.   
 
 
 
4.4 Early Withdrawal of Participants  
 
4.4.1 Participant Withdrawal, Data Collection, and Follow -Up 
Parti cipants may withdraw voluntarily from the study at any time. Participants will  be withdrawn 
from the study by [CONTACT_978]/Sponsor if a participant : 
 
• experiences a seizure,  
• experiences a DSM -5-confirmed treatment -induced mania,  
• is non -compliant with study procedures; or  
• endorsed illicit drug use or has a positive urine drug screen during the study  
 
The PI [INVESTIGATOR_33560] a participant  if he/she believes that for safety reasons it is in the best 
interest of the participant  to be withdrawn.  
 
Discontinuation information [e.g., date and the reason(s) for discontinuation] will be recorded in 
the Participant ’s CRF ( Case Report Form ). Participants  who discontinue prematurely should 
complete the Week [ADDRESS_74440] TMS treatment 
session. See the Schedule of Events for the specific procedures to be performed at this 
discontinuation visit.   
 
Participants withdrawn from the study due to an AE will be followed up for 30 days or until 
resolution. Participants  withdrawn from the study will not be replaced, regardless of the reason 
for withdrawal. An effort will be made to determine why a participant  does not return for the 
required visits or is dropped from the study. This information will subsequently be recorded on 
the participant’s  CRF. Participants  will be encouraged to remain compliant with all expected 
study visits.  Non -adherence to expected study visits will be documented and may result in 
removal from the study.  This will be clearly discussed during the consent/assent process and 
reinforced throughout the study through regular screening for issues with compliance.  
 
[CONTACT_68314] will assist with clinical referral for all participants who voluntarily withdraw from 
the study or are withdrawn by [CONTACT_68288].  Specifically, [CONTACT_68314] will offer 
ongoing clinical care or community referrals based on the preference of the participant.  
 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
36 
 5 Study Device  
5.1 Description  
The NeuroStar TMS Therapy® System is a computerized electromechanical instrument that 
produces and delivers brief duration, rapi[INVESTIGATOR_68236] (pulsed) magnetic fields to induce 
electrical currents in localized regions of the cerebral cortex.  It is a non -invasive tool used for 
the treatment of Participant s with MDD who have not achieved sufficient clinical benefit from 
antidepressant pharmacotherapy.  The NeuroStar TMS Therapy System has bee n FDA -cleared 
for use in adults .  NeuroStar XPLOR® is a clinical research option for the NeuroStar TMS 
Therapy System that provides features necessary to conduct randomized controlled trials and 
other TMS research.  The active treatment modality is essentially the same for both the 
NeuroStar TMS Therapy System and NeuroStar XPLOR.   
 
The NeuroStar XPLOR TMS System consists of the following equipment and software:  
 
• Mobile Console (includes processor module, power module, mast, gantry, halo, and 
display arm)  
• System Software; the XPLOR option also includes a dedicated system software 
application (software version 1.7.5 or greater) with its own dedicated database of 
participant treatment history, TMS TrakStar® application, and TrakStar database that 
operates only with the corresponding XPLOR Software, maintaining isolation, security, 
and data integrity of the research.  
• TMS TrakStar® Data Management System software  
• Therapy Coils included with the XPLOR option is a set of three TMS coils:  
o a blinded sham or placebo coil; the sham coil is acoustically matched to protect 
the integrity of the blind,  
o a blinded active coil, and  
o a standard treatment coil that can be used for performing motor threshold level 
determination or open -label treatment.  
• Head Support System (includes laser positioning aid and coil positioning guide)  
• Treatment Chair  
• Positioning Cushions (to enhance comfort and positioning of the participant  in the 
required posture for the duration of the treatment session)  
 
The NeuroStar TMS Therapy System also requires supplies and disposables for each treatment 
session:  
• Head Cushion Liner  
• Head Side Pad Liner  
• Head Positioning Straps  
• Earplugs  
• SenStar® Treatment Link (a single -use medical device)  
• Used SenStar Treatment Link Return box  
 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74441] of an assigned 3 -digit identifier. Participants will be 
identified by [CONTACT_68289]. The 
PI/Study Sponsor will maintain a master list linking Participant  names and the identifying 
information indicated above  
 
A Phase I randomization schedule will be generated by [INVESTIGATOR_124]. Nakonezny (Study biostatistician) . 
Participant s will not be randomized until all entry (inclusion and exclusion) criteria have been 
met and all pre -study procedures have been satisfactorily completed. After stratification based on 
ICF biomarker status, e ligible participants will be randomly assigned to receive one of the two 
treatment regimens ( 1 Hz or 10 Hz rTMS ), and the next available randomization number for the 
participant ’s stratum will be recorded in the screening log and on the participant ’s CRF. 
Randomization numbers may not be reassigned.  A permuted -block procedure will be used to 
randomly assign the treatment conditions, with a fixed block size for each stratum.   Phase II is a 
trial of cTBS or iTBS for Phase I participants who did not have an adequate clinical response in 
Phase I.   Participants will be assigned to 2 weeks of cTBS if their intr acortical facilitation 
measure is >1.5 (building on the current speculation that cTBS would be expected to decrease 
cortical excitability and ICF measures).  Participants will be assigned to 2 weeks of iTBS if their 
ICF (baseline assessment for TBS extension trial) is < 1.5.   
 
Collection of ICF and TMS neurophysiology measures:  TMS data will be collected with 
standard procedures published previously.65 Participants  are seated in a comfortable chair during 
the procedure.  All participants and research team members wear ear plugs during testing 
sessions. Surface electromyography (EMG) readings are recorded from the abductor pollicis 
brevis (APB) muscle .  The research team will ensure participant s maintain relaxation during the 
procedures with audio feedback tests. TMS stimulation will be applied to the hand area of the 
contralateral cortex with a figure -of-eight magnetic coil (with a coil diameter of 70 mm on each 
loop) using the Magstim [ADDRESS_74442] at 45 degrees laterally from the midline to determine resting 
motor threshold.  The optimal coil position is located by [CONTACT_68290] 1 -cm increments 
over the motor cortex. The resting motor threshold (RMT) is defined as the stimulation intensity 
which elicits a motor evoked potential (MEP) of > 50 microvolts in 5 of 10 trials with a relaxed 
APB muscle. For ICF measurements, a subthreshold conditioning stimulus (CS) which is set to 
80% of RMT precedes a suprathreshold test stimulus (TS), which is calibrated to produce an 
average MEP of 0.5 to 1.5 millivolt peak -to-peak amplitude in the contralateral APB muscle. 
Conditioning stimuli are delivered to the motor cortex prior to the TS in one of five random 
interstimulus intervals (ISIs): 2 msec, 4 msec for ICI; 10 msec, 15 msec, and 20 msec for ICF. 
Changes in TS MEP amplitude of each ISI are expressed as a percentage of the mean 
unconditioned MEP amplitude. Administration of tests is counterbalanced to prevent order 
effects. Please see Section 16, Appendix B for detailed methodology for collection of ICF and 
TMS neurophysiology measures.  
 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
38 
 5.3 Preparation and Administration /Impl antation  of Investigational  Device  
 
Administration of TMS treatment will be consistent with procedures outlined in the NeuroStar® 
User Manual and User training documentation.  
 
Motor Threshold Determination Procedure – per NeuroStar User Manual  
Participants in phase I (1 Hz vs. 10 Hz) will receive treatment parameters that have been safely 
and feasibly utilized in adult and adolescent studies.   For 1 Hz and 10 Hz (Phase I) sessions, 
stimulation will occur at 120% magnetic field intensity relative to the participant’s resting motor 
threshold (MT).  In phase II (cTBS vs. iTBS) stimulations will occur at 80% of the magnetic 
field intensity relative to the participant’s resting motor threshold.  
  
Treatment  
 
Partici pants in Phase I will be stratified based on ICF testing (high or low) at baseline.  An ICF 
of >1.5 at baseline is considered “high” and an ICF ≤ 1.5 is considered “low”.  Based on our 
prior work and review of literature, a sample of depressed adolescents will have an even 
distribution of high and low ICF values.  After stratification, adolescents are randomized to 
either LDLPFC  1 Hz rTMS with 2400 continuous pulses per session at 120% motor threshold or 
LDLPFC  10 Hz rTMS with 4 seconds on 36 seconds off for 2400 pulses each session at 120% of 
resting motor threshold.  Hence sessions in each treatment arm with two different types of rTMS 
(1 Hz and 10 Hz) will have identical intensities (120% motor threshold) durations (40 minutes), 
number of pulses  (2400), and treatment location (LDLFPC) .  Up to [ADDRESS_74443] day of Taper Week 3. We will deliver 
therapeutic rTMS sessions with a Neurostar XPLOR system magnetic stimulator.  The research 
team will localize rTMS treatment sites with the Beam F3 method.  Prior research demonstrates 
that this is a valid and reliable method for scalp location of the dorsolateral prefrontal cortex with 
comparable results to more expensive, time intensive, MRI -guided  approaches. 87 Our prior 
research demonstrates that the Beam F3 method is a feasible and reliable method for rTMS 
treatment localization in adolescents.69 Efficacy measures (CDRS -R) and TMS biomarkers will 
be collected at baseline and weekly .  The TMS biomarker panel includes ICF, Motor threshold 
(MT) Short -interval intracortical inhibition (SICI), long -interval intracortical inhibition (LICI), 
and cortical silent period (CSP).  
 
Participants  in Phase II will be assigned to 2 weeks of cTBS if their intracortical facilitation 
measure (baseline assessment for TBS extension trial) is >1.5.  Participants will be assigned to 2 
weeks of iTBS if their ICF (baseline assessment for TBS extension trial) is   < 1.5.  Extension 
trial TBS will be applied to the LDLPFC with the Beam F3 method. Participants  receiving cTBS 
will receive 10 daily (5 sessions per week for two weeks) 120 second trains of uninterrupted TBS 
for 1800 pulses at 80% motor th reshold. Participant s receiving iTBS will receive 10 daily  (5 
sessions per week for two weeks) 2 second trains every 10 seconds for a total of 570 seconds for 
1800 pulses at 80% motor threshold.  Efficacy measures (CDRS -R) and TMS biomarkers will be 
collected at baseline, 1 week, and 2 weeks.  The TMS biomarker panel includes ICF, Motor 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
39 
 threshold (MT) Short -interval intracortical inhibition (SICI), long -interval intracortical inhibition 
(LICI), and cortical silent period (CSP).  
 
Safety Precautions for Seizures and Cardiogenic Syncope during Phase I and Phase II 
TMS sessions.  
 
We will follow our standard lab procedures for screening to minimize the risk of seizures and 
syncope, monitoring during treatment sessions, and immediately addressing any induce d seizures 
or syncope during TMS sessions.  
 
With regard to the potential for seizures, all patients will be carefully screened for current or 
historical factors that may increase the risk of seizures (see Exclusion criteria). The Transcranial 
Magnetic Stimulation Adult Safety Screen (TASS) will be used to specifically query for any 
potential seizure or syncope risks. Neurologic disease which may increase the risk for seizures is 
part of the exclusion  criteria.74,75 Patients undergoing TMS in the proposed study will not be 
taking medications which could potentially lower their seizure threshold. All TMS sessions will 
be supervised by a physician located in the treatment suite  and all personnel involved will be 
provided with training in the identification of potential prodromal signs or symptoms of a 
seizure, particularly the identification of more subtle behavioral events which may herald the 
occurrence of a frontal lobe seizure, such as changes in level of consciousness or inattention.   
 
All TMS sessions  will be conducted in the neurostimulation suite with access  (within minutes)  to 
medical facilities and life-support equipment in the event a seizure should occur.   
 
Monitoring for Seizures during TMS sessions . 
 
Seizure monitoring will be by [CONTACT_68291].  This includes visual monitoring for 
signs of seizures and twitching of muscles, including the abductor pollicis brevis and the first 
dorsal interosseous  muscles of the contralateral hand. The visual observation monitoring will 
include monitoring for behavioral events such as changes in level of conscious ness or 
inattention.  One or more research team members will be in the room with the participant at all 
times during TMS sessions for visual observation.  At a minimum one TMS technician (with 
specialized onsite and national training on the delivery of TMS, visual monitoring for signs of a 
seizure, and training in seizure management) will be in the room with the participant at all times 
during the TMS session with a study physician in the TMS treatment suite.  
 
Seizure Management  
 
The TMS technician and physician i nvestigators have the capability to manage a seizure if it 
were to occur. The Mayo Clinic Neurostimulatio n Lab has direct access (within minutes  as it is 
in the same hospi[INVESTIGATOR_307] ) to emergency medicine services.  
 
In the event of a seizure  or syncopal event , the supervising physician  will initiate appropriate 
clinical care as defined within the clinical rTMS practice.   The Pediatric Code Team will also be 
called immediately. Attention must be taken to minimize the risk of aspi[INVESTIGATOR_1516], and when 
possible guiding the patient into the left lateral decubitus position is d esirable.  Because seizures 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
40 
 in the context of TMS  are brief (typi[INVESTIGATOR_897] <60 seconds) and without serious physical sequelae, 
efforts will be focused on preventing complications of the seizure rather than initiating any 
specific medication that is not required unl ess a seizure is prolonged.   The Pediatric Code Team   
is a hospi[INVESTIGATOR_307] -based pediatric  rapid response team who will arrive within minutes with life -support 
equipment (oxygen, suction, blood pressure monitor, CPR equipment) and 
anticonvulsant/antiepi[INVESTIGATOR_68247].  The Pediatric Code Team and the supervising TMS 
study physician will escort the participant to the emergency  medicine  department upon 
stabilization (located in the same hospi[INVESTIGATOR_68248]).  To date, status epi[INVESTIGATOR_68249].47,74,75 However, in the rare event this occurs, the 
participant will be treated in the emergency medicine department with access (within minutes) to 
neurological consultation.  
 
If a seizure occurs during the study, TMS treatment as part of the study will be discontinued.  
Ongoing monitoring of mood and neurocognitive symptoms per the study protocol will be 
offered.  Any seizure will be reported to the Mayo Clinic IRB, Data and Safety Monitoring 
Board ( DSMB ), Neuronetics,  and the FDA as required per agreements, regulations, and policies . 
 
5.4 Packaging and Labeling  
The NeuroStar XPLOR® Therapy System will be clearly labeled with the following warning:  
 
“CAUTION – Investigational Device. Limited by [CONTACT_4496] (or [LOCATION_002]) law to 
investigational use”  
 
5.5 Blinding of Study  
 
In both phases of the study (phase I and phase II) participants and study team members 
completing clinical rating scales (Drs. Croarkin, Romanowicz, or other designated and trained 
clinical raters) will be blinded to treatment assignment.  The study team member completing 
clinical rating scales will not be allowed in the treatment suite during therapeutic rTMS sessions 
(10 Hz, 1 Hz, iTBS , or cTBS).  We will recruit adolescent participants with no prior TMS 
exposure or experience and maintain blind to rTMS treatment assignment (1 Hz or 10 Hz  for 
phase I and cTBS or iTBS for phase II ).  A pre -post treatment expectancy and experience form 
will ask that participants and parents gues s which treatment (1 Hz, 10 Hz, iTBS, or cTBS ) was 
received .88 
 
5.6 Receiving, Storage, Distribution and Return  
5.6.1 Receipt of Investigational Devices  
NeuroStar XPLOR® TMS Therapy System will be delivered to the Principal 
Investigator /Sponsor  and installed by [CONTACT_68292].  
 
Upon receipt of the NeuroStar and study treatment supplies, an inventory will be performed and 
a device accountability log completed by [CONTACT_68293].  The designated study staff will 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
41 
 count and verify that the shipment contains all the items noted in the shippi[INVESTIGATOR_68250].  Any 
discrepancies or damaged or unusable devices in a given shipment will be documented in the 
device accountability log.  The Investigator at each study site will notify Neuronetics 
immediately of any discrepancies or damaged or unusable products.   
5.6.2 Storage  
The supplies and disposables required for each treatment will be stored in a supply station 
separate from clinical practice stock at each site.  
5.6.3 Distribution of Study Device  
All participants  will be treated using a new single -use treatment disposable, or SenStar® 
Treatment Link, from their treatment site at the start of every new treatment.  The treatment 
packs and SenStar Treatment Links will be stored in an area that is separate from clinical 
practice stock.  Regular reconciliation of SenStar Treatment Links received from Neuronetics, 
SenStars used during study treatments, and SenStars remaining will be performed.  This 
reconciliation of the inventory will be logged in the Device Accountability Log, signed, and 
dated.  Any discrepancies noted will be documented, Neuronetics will be notified, and an 
investigation will be conducted to determine the cause of the discrepancy.  Any SenStars 
disposed of for any reason other than use for the study will be documented in the Device 
Accountability Log at the time of disposal.  
5.6.4 Return or Destruction of Study Device  
NeuroStar devices and/or XPLORs that are loaned to the study site for purposes of this study will 
be returned to Neuronetics at conclusion of the study by [CONTACT_68294].  SenStars® that 
are remaining in the site study research inventory at the completion of the study will be packaged 
and returned to Neuronetics.  
 
5.7 Participant  Compliance Monitoring  
 
Non-adherence to the assigned treatment regimen is defined as missing  ≥3 treatments in daily 
sequence, or missing more than 20% of the total number of treatment sessions occurring during 
the 6 weeks of acute treatment (does not include taper treatments) as outlined in the schedule of 
events (i.e., 100% compliance = 30 total treatments).  However, if the participant  does miss a 
treatment, the participant  must not go more than 3 calendar days without a treatment session.  
Treatments missed during the taper visits are considered protocol deviations.  Participant s who 
are unable to comply with this schedule may be withdrawn from the investigational treatment 
portion of the study.  If a participant  receives more than the prescribed number of pulses (i.e. 
[ADDRESS_74444]), this would be considered an overdose and documented on the SAE 
form and reported to the IRB and US FDA.  
 
5.8 Prior and Concomitant Therapy  
 
5.8.1 Documenting Prior and Concomitant Therapy  
 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74445] 2 years.  All other medications and therapi[INVESTIGATOR_68251].  All relevant information will be recorded on the 
Participant s CRF.  The antidepressant treatment history form (ATHF) will be completed to 
quantify treatment history.  
5.8.2 Permitted Concomitant Therapy  
Zaleplon, zolpi[INVESTIGATOR_6730], or zopi[INVESTIGATOR_11123] (1 dose nightly) as needed for treatment emergent insomnia or 
lorazepam (up to 2 mg daily) for treatment emergent anxiety, may be administered for up to 14 
doses during Phase I and an additional 5 doses during Phase II.  The use of alternative hypnotics 
or anxiolytic compounds requires prior approval from the PI/Sponsor  ([CONTACT_68314]) .  Hormonal 
contraceptives are allowed if the participant  has been on a stable dose for at least [ADDRESS_74446] be 
approved by [CONTACT_978]/Sponsor  ([CONTACT_68317]) . Please see appendix A for further information.   
5.6.3 Prohibited Concomitant Therapy  
Any medication administered for the treatment of any psychiatric or neurologic disorder or any 
other known CNS active drugs, including herbal, over -the-counter, and homeopathic 
medications, MAOIs, other antidepressants, antipsychotics, stimulants and mood stabilizers are 
prohibited during this study ( See Appendix A, Concomitant Medication Exclusion List ).  Use of 
Zaleplon, zolpi[INVESTIGATOR_6730], zopi[INVESTIGATOR_68252] (see above) or 
beginning a new regimen of hormonal contraception may lead to excluding the participant  from  
the stu dy. 
6 Study Procedures  
 
6.1 Phase I Visit 1  (Screening)  
 
Table [ADDRESS_74447] (if applicable)  will be completed.  Baseline 
assessments may be completed  at this time as well in the interest of decreasing patient burden 
related to study procedures  (see Table 3).  
 
Once eligibility criteria are met and interest in the MRI /MRS  is indicated, the subject will report 
to the University of Minnesota Center for Magnetic Resonance Imaging for the 3 and 7 Tesla 
MRI Scan s.  This procedure needs to be completed prior to the Baseline Visit.  
 
6.2 Phase I Visit 2  (Baseline)  
 
Assessments will be completed (see Table 3) ,  TMS neurophysiology measures are collected ,   
and the participant is stratified as described previously based on ICF (ICF -15 % MEP amp)  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
43 
 biomarker status.  The participant is randomized to 1 Hz or 10 Hz rTMS.  Based on  participant 
preference, the baseline visit can be scheduled on a Monday to facilitate the initiation of 
investigational rTMS treatment (1 Hz or 10 Hz based on randomization). Otherwise, the 
participant will be scheduled to initiate the first investigational rTMS treatment day  as 
appropriate based on the patient’s schedule and staffing availability . 
 
6.[ADDRESS_74448] telephonically if necessary .  
Participants will undergo weekly depression severity measures and TMS neurophysiological 
measures (see Table 3).   
 
Table 2. Description of Assessments  
 
Assessment  Description  
Abnormal Involuntary 
Movement Scale (AIMS)  Collected at the screening visit and at weekly treatment visits, 
posttreatment, and 6 -month follow up visit.  This assessment is to 
screen and monitor twitching, trembling, and dyskinesias.  
Antidepressant Treatment 
History Form (ATHF)  Collected at baseline to systematically document prior psychotropic 
medication exposure and for quantification of treatment resistance 
(number of failed antidepressant trials with an adequate dose and 
duration).  
Adverse events  Participant s will be evaluated for adverse events at each visit. Serious 
adverse events (SAEs) will be reported as they occur to the Mayo 
Clinic IRB and [LOCATION_003] FDA (as per regulations). Systematic data 
collection focused on adverse events will include the Pediatric 
Adverse Event Rating Scale and Physical Symptom Checklist. These 
rating scales will be administered at baseline, weekly (during all 
rTMS, cTBS, and iTBS treatment weeks), at the 6 month follow up 
visit, and at study exit.  
Auditory thresholds  Participant s will undergo audiometry testing at baseline and upon 
completion of 6 week rTMS (1 Hz or 10 Hz) and once again (if 
applicable) after the two week open extension trial (of either cTBS or 
iTBS).  
Beck Depression Inventory -II This is a validated, 21 -item, self -report measure with a range of 0 -63. 
Collected at baseline, weekly during treatment, posttreatment, and 6 
month follow up visit.  
CDRS -R – Childhood 
Depression Rating Scale – 
Revised  This is a validated, 17 -item, clinical rating tool to assess severity of 
depression. Parents provide input into 14 of the items. Total possible 
scores range from 17 to 113. Collected at baseline, weekly during 
treatment, posttreatment, and 6 month follow up visit.  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
44 
 Assessment  Description  
CGI-S– Clinical Global 
Impressions Severity Scale  A standard measure of symptom severity and treatment response.  
Collected at baseline, weekly during treatment, posttreatment, and 6 
month follow up visit.  
Center for Magnetic Resonance 
Research Safety Screen 
(CMRR)  This assesses subject safety to go in the magnet room and undergo 3T 
and 7 MRI/MRS.  This will be completed at Mayo Clinic and CMRR  
C-SSRS – Columbia Suicide 
Severity Rating Scale  This is collected to assess lifetime suicidal ideation and behavior prior 
to pa rticipation, reassessed weekly during 6 week trial of 1 Hz vs 10 
Hz rTMS  (phase I)  and if applicable 2 week extension trial of cTBS or 
iTBS  (phase II ) during treatments, posttreatment, and 6 month follow 
up visit.  
CTQ – Childhood Trauma 
Questionnaire  A 28 item self -report scale used to screen for a history of adversity. 
Collected at baseline.  
Edinburgh Inventory for 
Handedness  Used to assess handedness of all Participant s. Collected at baseline.  
Mini International 
Neuropsychiatric Interview 
(M.I.N.I)  A structured psychiatric interview (M.I.N.I. for age 18 and M.I.N.I 
Kid for ages 12 -17). Collected at baseline.  
 
NIH Toolbox Cognition Battery  http://www.healthmeasures.net/explore -measurement -systems/nih -
toolbox  
 
Cognition measures: http://www.healthmeasures.net/explore -
measurement -systems/nih -toolbox/intro -to-nih-toolbox/cognition  
 
The NIH Toolbox Cognition Battery , recommended for ages 7+, 
consists of tests of multiple constructs. It yields individual measure 
scores and the following summary scores:   Education, Handedness, 
Attention (Flanker Inhibitory Control and Attention Test),  Epi[INVESTIGATOR_6368] (Pi[INVESTIGATOR_17121], and Auditory Verbal 
Learning Test), Executive Function (Dimensional Change Card Sort 
Test, Flanker Inhibitory Control and Attention Test), Language 
(Pi[INVESTIGATOR_17122], Oral Reading Recognition Test), Processing 
Speed (Pattern Comparison Processing Speed Test), Working Memory 
(List Sorting Working Memory Test).  Collected at baseline, 
posttreatment, and 6 month follow up.  
 
PDS – Pubertal Development 
Scale and Tanner Staging  A self -report questionnaire and line -drawings used to evaluate level of 
pubertal development. Collected at baseline.  
Pre/Post Treatment Expectations 
and Experience Questionnaire 
(Adolescent and Parent)  Assesses adolescent and parent blinding to treatment arm (1 Hz or 10 
Hz) and expectations for treatment outcome. Collected at baseline and 
posttreatment.  
SHAPS -Snaith-Hamilton 
Pleasure Scale  This is a 14 item, self -report measure of validated measure of hedonic 
capacity. Collected at baseline.  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
45 
 Assessment  Description  
Pediatric Adverse Event Rating 
Scale  This is a 51 item; self-report measure collected at baseline, weekly 
during rTMS treatments, posttreatment, and at [ADDRESS_74449]  This is a 46 item measure to be collected by [CONTACT_3476] (under the 
supervision of the PI) at baseline, weekly during rTMS treatments, 
posttreatment, and at 6 month follow up visit for adverse event 
monitoring.  
SIT-R3 – Slosson Intelligence 
Test – Revised  A rapid, validated index of intellectual ability. Its items cover six 
cognitive domains: Information, Comprehension, Quantitative, 
Similarities and Differences, Vocabulary, and Auditory Memory. 
Collected at baseline , if PI [INVESTIGATOR_68253].  
TASS – Transcranial Magnetic 
Stimulation Safety Screen  This safety screen is completed prior to TMS for confirmation patient 
safety. Collected at baseline.  
UCSD Brief Assessment of 
Capacity to Consent (UBACC)  This will be given to patients that are 18 years of age who are interested in 
participating in the MRI/MRS scans at CMRR of age during informed 
consent. This assesses the patient’s understanding of the MRI/MRS portion 
of the study.  
Vital Signs  (Pulse, blood pressure, height, and weight) will be collected at 
baseline, upon completion of 6 week rTMS (1 Hz or 10 Hz) once 
again (if applicable) after two week open extension trial (of either 
cTBS or iTBS), and at 6 month follow up visit.  
YMRS -Young Mania Rating        
Scale  This is an 11 item  measure used to assess for manic symptoms.  The 
YMRS scale will be completed at baseline and repeated during the 
course of study participation if symptoms of mania occur in a study 
participant.  If the YMRS is positive, A MINI/MINI -Kid will be 
repeated to evaluate for mania.  If the study participant meets full 
DSM -5 criteria for mania or hypomania he or she will be discontinued 
from the study and followed clinically.  
TMS Neurophysiology 
Measures ( MT, SICI, ICF, LICI, 
CSP)  Single (motor threshold and cortical silent period) and paired -pulse 
(intracortical facilitation, short -interval cortical inhibition, long -
interval cortical inhibition) .  TMS neurophysiology measures will be 
collected in depressed adolescent participant s at baseline, weekly 
during six weeks of rTMS treatment with 1Hz or 10 Hz  rTMS (phase 
I), posttreatment, and weekly for 2 weeks for depressed adolescent 
participant s in a, trial of cTBS or iTBS (phase II).   
 
  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
46 
  
Table 3 Phase I Assessments  
 
 
Phase I  1-Week  
Prestudy  6-Week  
Treatment (1 Hz vs. 10 Hz)  3-Week  
Post-
Treatment 
Taper  6- 
Mont
h  
Follo
w Up  
Week  Wk –2 to -
1a 
(Screening)  Wk 0a 
(Baselin
e) W
k 
1b W
k 
2b W
k 
3b W
k 
4b W
k 5 
b Wk 
6b,c/E
T Wk 
1 Wk 
2 W
k 
3  
Day(s)  -7a 0a 1-5 8-
12 15-
19 22-
26 29-
35 36-42 43-
49 50-
56 57
-
63  
Informed 
Consent/Assent/HIPA
A X     
       
CMRR Safety Screen 
(prior to MRI/MRS)  X     
  X     
UCSD Brief 
Assessment of 
Capacity to Consent 
(UBACC) (only 
patients age 18 
participating in 
MRI/MRS scans at 
CMRR)  X 
     
       
MRI /MRS  
Stud y(Before Baseline 
Appt.)  X     
  X     
Transcranial 
Magnetic Stimulation 
Adult Safety Screen 
(TASS ) X     
       
Antidepressant 
Treatment History 
Form (ATHF)  X     
       
Abnormal 
Involuntary 
Movement Scale 
(AIMS)  X  X X  
X X X X  
X  
X  
X  
X 
MINI / MINI -Kids  X            
CTQ   X           
PDS   X           
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
47 
 Phase I  1-Week  
Prestudy  6-Week  
Treatment (1 Hz vs. 10 Hz)  3-Week  
Post-
Treatment 
Taper  6- 
Mont
h  
Follo
w Up  
Week  Wk –2 to -
1a 
(Screening)  Wk 0a 
(Baselin
e) W
k 
1b W
k 
2b W
k 
3b W
k 
4b W
k 5 
b Wk 
6b,c/E
T Wk 
1 Wk 
2 W
k 
3  
Day(s)  -7a 0a 1-5 8-
12 15-
19 22-
26 29-
35 36-42 43-
49 50-
56 57
-
63  
SHAPS   X           
Pre/Post -TEEQ -P  X      X     
Pre/Post -TEEQ -A  X      X     
Efficacy Assessments              
BDI-II X X    X   Xc,d X  Xd  
CDRS -R X X X X X Xd X Xc,d X X Xd X 
CGI -S X X    X   Xc,d X  Xd X 
Neuropsychological 
Assessments       
        
NIH Toolbox   X       Xc,d    X 
SIT-R3  X           
YMRSd  X            
C-SSRS  X X Xd Xd Xd Xd Xd Xc,d Xd Xd Xd X 
Safety Assessments              
Physical 
examination  X     
       
Vital Signs  X        Xc X    
Urine drug screen  X            
Pregnancy teste X            
Audiometry 
assessment   X    
  Xc    
X 
Physical Symptom  
Checklist   X X X X X X X    X 
   Pediatric Adverse 
Event Rating  
         Scale   X X X X X X X        X 
Adverse Events  X ------------------------------------------ --------------------------- ------------------------------ X  
Prior/Concomitant 
Treatment  X ---------------------------------------------------------------------------------------- ----------- X  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
48 
 Phase I  1-Week  
Prestudy  6-Week  
Treatment (1 Hz vs. 10 Hz)  3-Week  
Post-
Treatment 
Taper  6- 
Mont
h  
Follo
w Up  
Week  Wk –2 to -
1a 
(Screening)  Wk 0a 
(Baselin
e) W
k 
1b W
k 
2b W
k 
3b W
k 
4b W
k 5 
b Wk 
6b,c/E
T Wk 
1 Wk 
2 W
k 
3  
Day(s)  -7a 0a 1-5 8-
12 15-
19 22-
26 29-
35 36-42 43-
49 50-
56 57
-
63  
Motor Threshold 
Determinationg   X    
       
TMS Treatment 
Session  
(daily  5 
weekdays/week)    X--
-Xb X--
-Xb X--
-Xb X--
-Xb X---
Xb X---Xb    
 
TMS neurophysiology 
measures (MT, SICI, 
ICF, LICI, CSP)   X X X X X X X    
 
Post-Treatment Taper 
TMS Session(s)  
(3X/Wk1, 2X/Wk 2, 
1X/Wk 3)           X X  
X 
   
a. A maximum of 7 days may elapse between the screening and baseline visits; a maximum of [ADDRESS_74450] day of the treatment wee k when 
assessments are required. YMRS to be completed if symptom indicating mania occurs.  If positive, a MINI/MINI -Kid must be repeated to 
determine if Participant  meets full DSM -[ADDRESS_74451] without the participant’s  permission. But if the participant’s  doctor believes that being pregnant 
may cause serious health problems, they may need to tell the parent/guardian the pregnancy test results.  
f. Adverse events occurring prior to randomization will be recorded as part of each patient’s medical history. Those AEs occurring following 
the first TMS treatment session through [ADDRESS_74452] TMS treatment session will be collected.  
g. In addition to the indicated day, Motor Threshold Determination (MT) may be repeated at any time during the course of the act ive TMS 
treatment sessions based on clinical assessment of the supervising physician.   
Medication treatment for emergent insomnia and emergent anxiety is permitted (refer to protocol for usage allowance).  Refer to 
Appendix A for the Concomitant Medication List.  
h. The following assessments will be completed once only for healthy controls at  the Mayo Clinic  site: Urine testing (drugs and pregnancy if 
female), vitals (blood pressure, pulse, height and weight), GUID (demographics) form, physical examination record,  Transcranial Magnetic 
Stimulation Adult Safety Screen, M.I.N.I. Kid, Children’s Depression Rating Scale, Columbia - Suicide Severity Rating Scale, Childhood 
Trauma Questionnaire, Clinical Global Impressions, Center for Magnetic Resonance Research Screening Form, Edinburgh Handednes s 
Inventory, Scale for Pubertal Development, Beck Depression Inventory -II, Authorization to Release Information (if applicable)  
 
Table 4 Phase II Assessments  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74453] size ( d~0.61) as it relates to the Primary Aim, an a priori  
sample size estimation and power analysis was performed for the repeated measures design  in 
the proposed study . The results suggest that a sample size of 25 participants per group  (N=120) 
achieves 80% power, at a 0.05 alpha level (two -tailed), to detect standardized group mean 
differences (Cohen’s d) as small as 0.6 1 in a 2 -treatment  by 2-biomarker status between -
Participant s group design with 6 (within -Participant s) repeated measurements of the primary 
outcome (depression severity) having a compound symmetry covariance structure, when the 
assumed within -Participant  correlation between observations ( depression severity ) on the same 
Participant  is ≤0.50 (0.50 was based on guidance from our preliminary rTMS work ).  We 
anticipate some dropouts (~ 20% based on treatment discontinuation results from our previous 
rTMS studies ). Thus, ~120 participants will be enrolled to allow for this expected rate of attrition 
with the intent of capturing a range of evaluable data for 100 participants. The Power Analysis 
and Sample Size (PASS) 2016 software, version 14.0.7, was used to carry out the sample size 
and power analysis . 89 Week  Week 1  Week 2  6 Month  
Follow -up 
Days  1-5 8-12  
Informed Consent/Assent         X   
Motor Threshold  X   
CDRS -R X X X 
CGI  X X X 
C-SSRS X X X 
TMS neurophysiology measures  
(MT, SICI, ICF, LICI, CSP)  X X  
AIMS  X X X 
Vital Signs  X X  
Physical Symptom   Checklist  X X X 
Pediatric Adverse Event Rating   Scale  X X X 
Audiometry assessment   X X 
NIH toolbox   X X 
Adverse Eventsf Daily  Daily   
Prior/Concomitant Treatment  Daily  Daily   
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
50 
  
We recognize that to definitively evaluate the relationship between rTMS Treatment (low 
frequency 1 Hz rTMS vs. high frequency 10 Hz rTMS) by [CONTACT_68295] (high baseline ICF 
vs. low baseline ICF) on depression severity —since this relationship has not been previously 
studied, we have no previous findings to guide effect size selection for the present effort, and the 
current study would be the first of its kind to examine this effect in depressed youth —we will 
possibly need a larger sample size than the [ADDRESS_74454] and to establish a proof of concept  so as to expand to a subsequent, 
larger -scale multi -center study.  Nevertheless, the current proposal will permit an evaluation of 
whether receiving low frequency (1 Hz) rTMS vs. high frequency (10 Hz) rTMS treatment 
according to patients’ baseline biomarker status (ICF) shows initial evidence of a relationship 
with improvement in depression severity in a depressed adolescent population.  
 
7.2 Statistical Methods  
 
 
Statistical Methods  
All statistical analyses will be carried out using SAS software, version 9.4 . The level of 
significance will be set at α = .05 (two -tailed) and, to address multiple testing (where applicable), 
p-values will be adjusted using the False Discovery Rate .  
 
Primary Aim  
Data Analysis Plan for Primary Aim 1 (Hypotheses 1a  ̶ 1d)  
 
Primary Continuous Outcome: CDRS -R Total Score  
Depression severity (measured by [CONTACT_68274] -R total) over the 6 -week study period will be the 
primary continuous outcome measure.  A linear mixed model analysis of repeated measures will 
be used to evaluate the rTMS Treatment (low frequency 1 Hz rTMS vs. high frequency 10 Hz 
rTMS) by [CONTACT_68295] (high baseline ICF vs. low baseline ICF) interaction effect on 
depression severity (CDRS -R total) over 6 weeks of rTMS in depressed adolescents. The model 
will contain fixed effects terms for rTMS treatment, biomarke r status, time, rTMS treatment × 
biomarker status interaction, and baseline CDRS -R total score as a covariate.  We will consider 
the inclusion of pubertal state and treatment resistance (as defined by [CONTACT_68296] [ATHF] score) during the study period as additional covariates in the mixed 
model.  Restricted maximum likelihood estimation, Type [ADDRESS_74455] 
fitting covariance structure. The sandwich (robust covariance matrix) estimator will also be 
considered. Least squares (LS) means will be estimated as part of the mixed model. Tests of 
Simple Effects will be examined so as to partition the interaction LS means effects; i.e., simple 
group main effects of biomarker status at each level of rTMS treatment (Hypotheses 1a, 1b) and 
simple group main effects of rTMS treatment at each level of biomarker status (Hypotheses 1c, 
1d) will be examined.  Cohen’s d and Hedge s' g will be calculated and interpreted as the effect 
size estimator for the between -Participant s group main effects. A separate linear mixed model 
repeated measures analysis similar to that described above will also be implemented over 6 
weeks of acute rTMS treatment and throughout the 6 -month follow -up period.  The PROC 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
51 
 MIXED procedures (mixed model approach) in SAS software will make use of all available data 
from all participants from the efficacy analysis set, and provide a robust mechanism for handling 
data that are assumed missing at random (see sensitivity analysis section below for MNAR).   
 
Secondary Aim  
Data Analysis Plan for Secondary Aim 2 (Hypotheses 2a  ̶ 2d)  
 
Secondary Continuous Outcome:  Intracortical Facilitation (ICF)  
Intracortical Facilitation over the 6 -week study period will be the secondary continuous outcome 
measure.  A within -Participant s linear mixed model analysis of repeated measures will be used to 
examine the change in ICF over 6 weeks of rTMS treatment in depressed adolescents.  We will 
consider the inclusion of pubertal state and treatment resistance (as defined by [CONTACT_68297]) 
during the study period as a covariate in the mixed model.  A mixed model analysis will be 
conducted on ICF for those who receive 6 weeks of low frequency (1 Hz) rTMS treatment 
(Hypothesis 2a) and, in a separate model, for those who receive 6 weeks of high frequency (10 
Hz) rTMS treatment (Hypothesis 2c).  Restricted maximum likelihood estimation, Type [ADDRESS_74456] squares (LS) will be used, with the Kenward -Roger 
correction  applied to the appropriate and best fitting covariance structure. The sandwich (robust 
covariance matrix) estimator will also be considered.  LS mean contrasts (between ICF 
measurement time periods) from the mixed model will also be examined.  A separate linear 
mixed model analysis similar to that described above will also be implemented over 6 weeks of 
acute rTMS treatment and throughout the 6 -month follow -up period.  A nonlinear mixed model 
will be considered (e.g., exponential decay/growth model) to estimate ICF over the 6 weeks of 
rTMS treatment (if the pattern of ICF values suggests that a nonlinear model is deemed 
necessary).  
 
A linear mixed model repeated measures analysis similar to that described above will also be 
used to examine the relationship between measures of ICF (as the response variable) and 
depressive symptoms (CDRS -R total as a time -varying covariate) over the 6 weeks of rTMS 
treatment.  We will consider the inclusion of pubertal state and treatment resistance (as defined 
by [CONTACT_45691]) during the study period as a covariate in the mixed model.  The parameter estimates 
(regression coefficients) will be interpreted from the solution for fixed effects in the mixed 
model analysis for those who receive 6 weeks of low frequency (1 Hz) rTMS treatment 
(Hypothesis 2b) and for those who receive 6 weeks of high frequency (10 Hz) rTMS treatment 
(Hypothesis 2d).  A separate linear mixed model analysis similar to that described above will 
also be implemented over 6 weeks of acute rTMS treatment and throughout the 6 -month follow -
up period. A nonlinear mixed model will be considered to estimate ICF over the 6 weeks of 
rTMS treatment from CDRS -R total (if the pattern of ICF and CDRS -R total suggests that a 
nonlinear model is deemed necessary).  
 
Data Analysis Plan for  Exploratory Aim 3  (MRI /MRS)   
 
A within -participants linear mixed model analysis of repeated measures will be used to examine 
baseline differences between depressed adolescents and healthy control adolescents (Hypotheses 
1 and 2); and the change in cortical MRS measures of GABA and Gln/Glu over [ADDRESS_74457]/Glu for those who receive 6 weeks of low frequency (1 Hz) rTMS treatment 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
52 
 (Hypotheses 3 and 4) and for those who receive 6 weeks of high frequency (10 Hz) rTMS 
treatment (Hypotheses 5 and 6).  A nonlinear mixed model will be considered (if the pattern of 
GABA and Gln/Glu values suggests that a nonlinear model is deemed necessary).  
 
Data Analysis Plan for Exploratory Aim 4   
 
Moderator Effects of Anhedonia and Adversity on Treatment Outcome of Depression Severity  
The multiple mediation/moderation path analytic model, as described in Preacher and Hayes will 
be used to estimate the direct effect as well as the total and specific indirect effects of rTMS 
treatment on depression severity (at the 6 -week endpoint) through each of the potential baseline 
moderators (anhedonia and adversity) operating in parallel and, via a separate model, in serial, 
while controlling for any potential demographics/patient characteristics (not designated as 
mediators/moderators), including pubertal state and treatment resistance (as defined by [CONTACT_68298]).  A test of the indirect effects will be conducted by [CONTACT_63676][INVESTIGATOR_68254] (95% bias -corrected) from 5,000 bootstrap samples. The procedures of the 
PROCESS computational SAS macro developed by [CONTACT_68299] -based multi ple mediation/moderation model.  
 
Sensitivity Analysis  
In this section we present a brief sensitivity analysis plan to address incomplete response patterns 
according to a missing not at random mechanism.  First, we will follow the outcome -based 
model framework of for longitudinal data with non -random missingness along with a model -
based approach proposed for modeling both the treatment response and the missing data 
process.90 That is, if deemed necessary, we will build longitudinal models for the data which 
includes a model for the dropout (or missing data) process so as to assess the sensitivity of the 
results about the dependence between dropout (or missingness) and treatment response.  
Additionally, if deemed necessary, we will consider implementing the semi -parametric shared 
parameter model approach as described in Tsonaka et al. (2009) to handle nonmonotonic 
nonignorable missingness for mixed -effects models.  A Pattern -Mixture Model will also be 
considered (if necessary). 90 The results from such (non -random dropout/missingness) models 
will then be compared with the results of the proposed standard methods (dropout or missing at 
random models) so as to assess the sensitivity of the results to the effect of dropouts (or 
incomplete response patterns according to a missing not at random mechanism).    
 
[ADDRESS_74458] (UADE)  
A UADE is any serious adverse effect on health or safety or any life -threatening problem or 
death caused by, or associated with, a device if that effect, problem or death was not previously 
identified in nature, severity, or degree of incidence in the investigational plan or IDE application 
(including a supplementary plan or application), or any other unanticipated serious problem 
associated with a device that relates to the rights, safety, or welfare of participants . 
 
Adverse Effect (Event)  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74459] medical occurrence in a participan t involved in clinical study of an investigational 
device; regardless of the causal relationship of the problem with the device or, if applicable, 
other study related treatment(s).  
 
Associated with the investigational device:   there is a reasonable possibility that the adverse 
effect may have been caused by [CONTACT_14882].  
 
Life-threatening adverse effect:  Any adverse effect that places the participan t, in the view of 
either the investigator or the sponsor, at immediate risk of death from the effect as it occurred .  
It does not include a reaction that, had it occurred in a more severe form, might have caused 
death.  
 
Serious adverse effect:  An adverse effect is considered “serious” if, in the view of either the 
investigator or the sponsor, it results in any of the following outcomes:  
• death  
• a life -threatening AE  
• inpatient hospi[INVESTIGATOR_1081]  
• a persistent or significant disability/incapacity  
• a congenital anomaly/birth defect.  
 
Unanticipated adverse effect: Any adverse effect, the nature, specificity, severity, or frequency 
of which is not consistent with the risk information in the clinical study protocol or elsewhere in 
the current IDE application.  
 
General Physical Examination Findings  
At screening, any clinically significant abnormality should be recorded as a preexisting 
condition.  At the end of the study, any new clinically significant findings/abnormalities that 
meet the definition of an adverse event must also be recorded and documented as an adverse 
event.  
 
Hospi[INVESTIGATOR_059], Prolonged Hospi[INVESTIGATOR_68255].  Any condition responsible for surgery should be documented as an 
adverse event if the condition meets the criteria for an adverse event.  
 
Neither the condition, hospi[INVESTIGATOR_059], prolonged hospi[INVESTIGATOR_059], nor surgery are reported as an 
adverse event in the following circumstances  
 
• Hospi[INVESTIGATOR_68034] a preexisting condition.  Surgery will not be reported as an outcome of an adverse 
event if the purpose of the surgery was elective or diagnostic and the outcome was 
uneventful  
• Hospi[INVESTIGATOR_14843], 
unless it is a worsening or increase in frequency of hospi[INVESTIGATOR_49849].  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74460] each participant to report any subsequent 
event(s) that the participant, or the participant ’s personal physician, believes might reasonably be 
related to participation in this study.   
 
Preexisting Condition  
A preexisting condition is one that is present at the start of the study.  A preexisting condition 
should be recorded as an adverse event if the frequency, intensity, or the character of the 
condition worsens during the study period.  
 
Unanticipated Problems Involving Risk to Participant s or Others (UPI[INVESTIGATOR_14845])  
Any unanticipated problem or adverse event that meets all of the following three criteria:  
• Serious : Serious problems or events that results in significant harm, (which may be 
physical, psychological, financial, social, economic, or legal) or increased risk for the 
Participant  or others (including individuals who are not research Participant s). These 
include: (1) death; (2) life threatening adverse experience; (3) hospi[INVESTIGATOR_059] - inpatient, 
new, or prolonged; (4) disability/incapacity - persistent or significant; (5) birth 
defect/anomaly; (6) breach of confidentiality and (7) other problems, events, or new 
information (i.e. publications, DSMB reports, interim findings, product labeling change) 
that in the opi[INVESTIGATOR_14846], safety, or 
welfare of the Participant s or others, or substantially compromise the research data, AND  
• Unanticipated : (i.e. unexpected) problems or events are those that are not already 
described as potential risks in the protocol, consent document, not listed in the 
Investigator’s Brochure, or not part of an underlying disease. A problem or event is 
"unanticipated" when it was unforeseeable at the time of its occurrence. A problem or 
event is "unanticipated" when it occurs at an increased frequency or at an increased 
severity than expected, AND  
• Related : A problem or event is "related" if it is possibly related to the research 
procedures.  
 
An adverse event  is any untoward, undesired, or unplanned event in the form of signs, 
symptoms, disease, or laboratory or physiological observations occurring in a person who has 
received NeuroStar TMS therapy (1 Hz, 10 Hz, cTBS, or iTBS).  The event need not be causally 
related to the NeuroStar device or the present clinical trial. An AE includes, but is not limited  to: 
 
• Any clinically significant worsening of a pre -existing condition;  
• An AE occurring from overdose (i.e., a dose higher than that described in the protocol) of a 
NeuroStar TMS device, whether accidental or intentional;  
• An AE occurring from abuse (e.g., use for non -clinical reasons) of a NeuroStar TMS device;  
• An AE that has been associated with the discontinuation of the use of a NeuroStar TMS 
device; a preexisting condition  is a clinical condition (including a condition being treated) 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
55 
 that is diagnosed before an informed consent form is signed  and is documented as part of the 
Participant ’s medical history.  
 
The questions concerning whether the condition existed before the start of the active phase of the 
study and whether it has increased in severity and/or frequency will be used to determine 
whether an event is a treatment -emergent AE (TEAE). An AE is considered to be a TEAE if  (1) 
it was not present when the active phase of the study began and is not a chronic condition that is 
part of the Participant ’s medical history, or (2) it was present at the start of the active phase of 
the study or as part of the Participant ’s medical history, but the severity or frequency increased 
during the active phase.  
 
Additionally,  important medical events  that may not result in death, be life -threatening, or 
require hospi[INVESTIGATOR_059], may be considered SAEs, based upon appropriate medical judgment.  
 
Life threatening refers to  immediate risk of death as the event occurred or use or continued use 
of the device or other medical product might have resulted in the death per the reporter. A life -
threatening event does not include an event that, had it occurred in a more severe form, might 
have caused death, but as it actually occurred, did not create an immediate risk of death.  
 
Hospi[INVESTIGATOR_17126]. Hospi[INVESTIGATOR_17127] a 
hospi[INVESTIGATOR_17128].  
 
Note that hospi[INVESTIGATOR_059] s planned before the start of the study , for a preexisting condition that 
has not worsened , do not constitute an SAE (e.g., elective hospi[INVESTIGATOR_68256] a 
preexisting condition that has not worsened during the study).  
 
If there is any doubt whether the information constitutes an SAE, the information should be 
treated as an SAE for the purpose of this study.  
 
8.[ADDRESS_74461] (UADE) will be recorded on the appropriate case report 
form  on the day of the occurrence.   Records of these events will be maintained and reports 
submitted to the FDA and IRB according to the regulatory requirements.  Expected clinical 
adverse events and nonsignificant (not serious) clinical adverse events will not be reported. 
Expected clinical adverse events and anticipated adverse device effects are those listed in Section 
1.4.1.  The PI/Sponsor ([CONTACT_68314]) and research team will follow all AEs, SAEs, and other 
reportable events until the event has subsided or values have returned to baseline, or in case of 
permanent impairment, until the condition stabilizes.  
8.[ADDRESS_74462] of the Participant ’s CRF. The information recorded should be based 
on the signs or symptoms detected during the physical examination and clinical evaluation of the 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
56 
 Participant . In addition to the information obtained from those sources, the Participant  should be 
asked the following nonspecific question:  "How have you been feeling since your last visit?" 
Signs and symptoms should be recorded using standard medical terminology.  On the case report 
form the treating physician will record the event, sign with their initials  and enter the current 
date.  After the treatment is completed, this process will be repeated.  The PI [INVESTIGATOR_1660] a Co PI [INVESTIGATOR_68257] a daily basis and will determine the event to be “Clinically 
Significant” or “Not Significant.” This process can be completed by [CONTACT_648], email or face to face.   
 
The following AE information must be included (when applicable): the specific condition or 
event and direction of change; whether the condition was preexisting (i.e., an acute condition 
present at the start of the study or history of a chronic condition) and, if so, whether it has 
worsened (e.g., in severity and/or frequency); the dates and times of occurrence; severity; causal 
relationship to the investigational device; action taken; and outcome.  
Causal relationship options and definitions are as follows:  
• Definitely related : Event can be fully attributable to administration of the investigational 
device.  
• Probably related : Event is most likely to be explained by [CONTACT_68300], rather than the Participant ’s clinical state or other agents/therapi[INVESTIGATOR_014].  
• Possibly related : Event is as likely explained by [CONTACT_68301], 
as by [CONTACT_68302] ’s clinical state or other agents/therapi[INVESTIGATOR_014].  
• Probably not related : Event is most likely to be explained by [CONTACT_68302] ’s clinical state 
or other agents/therapi[INVESTIGATOR_014], rather than the investigational device.  
• Definitely not related : Event can be fully explained by [CONTACT_68302] ’s clinical state or other 
agents/therapi[INVESTIGATOR_014], rather than the investigational device.  
When assessing the relationship between an investigational product/protocol and an AE, the 
following parameters are considered:  
• Temporal relationship between the investigational device/protocol and the AE  
• Biologic plausibility of relationship  
• Participant s’ underlying clinical state or concomitant agents/therapi[INVESTIGATOR_014]  
• Where applicable , whether the AE abates on discontinuation of the investigational device 
(dechallenge)  
• Where applicable, whether the AE reappears on repeat exposure to the investigational device 
(rechallenge)  
SAEs that are not investigational device -related may nevertheless be considered by [CONTACT_68303] (or designee) to be related to the conduct of the 
clinical study, i.e., to a Participant 's participation in the study.  
For this study, the treatment follow -up period for adverse events is defined as [ADDRESS_74463] study visit.  Follow up will be documented in the Participant s study file.  
 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
57 
 Per Mayo Clinic policy: “ All health care providers in the State of Minnesota are mandated 
reporters under the Minnesota Maltreatment of Minors Act. ” All study staff are made aware of 
this policy and will remain in compliance with associated reporting procedures when necessary.  
8.3.1 Sponsor -Investigator Reporting, Notifying Mayo IRB  
 
The sponsor -investigator will report to the Mayo IRB any UPI[INVESTIGATOR_68258] -UPI[INVESTIGATOR_68259].  
 
8.3.2  Sponsor -Investigator Reporting: Notifying the FDA  
 
The sponsor -investigator will report to the FDA all unanticipated adverse device effects 
according to the required reporting timelines, formats and regulations.  
 
Additionally, per FDA request, all blurred vision adverse events will be reported to the FDA 
within 5 business days.  
 
The sponsor -investigator will submit a completed FDA Form 3500A  to the FDA’s Center for 
Devices and Radiological Health for any observed or reported adverse effect that is determined 
to be an unanticipated adverse device effect.  A copy of this completed form will be provided to 
the DSMB and all participating sub -investigators.  
 
The completed FDA Form 3500A will be submitted to the FDA as soon as possible and, in no 
event, later than [ADDRESS_74464].  
 
If the results of the sponsor -investigator’s follow -up evaluation shows that an adverse effect that 
was initially determined to not constitute an unanticipated adverse device effect does, in fact, 
meet the requirements for reporting; the sponsor -investigator will submit a completed FDA Form 
3500A as soon as possible, but in no event later than [ADDRESS_74465] in light of any previous, similar 
report(s).  
 
Subsequent to the initial submission of a completed FDA Form 3500A, the sponsor -investigator 
will submit additional information concerning the reported adverse effect as requested by [CONTACT_1556].  
 
 
Reporting Process  
Unanticipated Adverse Device Effect reports will be submitted on FDA Form 3500A.  
The contact [CONTACT_68304]:  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74466]  
Silver Spring, Maryland [ZIP_CODE] -0002  
 
8.3.3 Deviations from the investigational plan.  
 
The sponsor -investigator shall notify Mayo IRB (see 21 CFR 56.108(a) (3) and (4)) of any 
deviation from the investigational plan to protect the life or physical well -being of a Participant  
in an emergency. Such notice shall be given as soon as possible, but in no event later than [ADDRESS_74467] the scientific soundness of the plan or the rights, safety, or welfare of 
human Participant s, FDA and IRB notification in accordance with 21 CFR 812.35(a) also is 
required.  
 
8.4 Unblinding  Procedures (Breaking the Blind)  
While the safety of the participant  always comes first, it is still important to seriously consider if 
unblinding the study therapy is necessary to ensure a Participant ’s safety.  In the event of a 
serious adverse device effect, the Investigator will carefully assess whether breaking the blind 
will critically affect how a Participant  is treated in response to the adverse effect and whether this 
knowledge outweighs the implications to the scientific soundness of the study.  In the case of 
most serious adverse effects, treatment would be discontinued and symptoms treated 
symptomatically.  In these instances, having this information would not significantly alter the 
treatment of the adverse effect(s).   
 
As an additional safeguard against bias, the DSMB has been charged with making the final 
recommendations for breaking the study bl ind 
 
If the decision to break the blind is made immediately upon learning of the adverse event, this 
information will be reported to the FDA and reviewing IRB at the time of initial adverse event 
reporting.  If the unblinding occurs after the initial reporting, the FDA will be notified of the 
action within ten working days from the time of breaking the blind.  The reviewing IRB will be 
notified according to their reporting guidelines if the decision is made to break the study blind 
after the initial reporting.  
 
8.5 Stoppi[INVESTIGATOR_68260] 4.4.1 in the 
discussion of Anticipated Risks.  
 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74468] every six months. Serious adverse events will be reviewed on a 
monthly basis, unless a more urgent review is requested.  Only under extreme circumstances or if 
it were determined that a high level of side effects was due to TMS, would the DSMB be 
charged with breaking the study mask.  
 
Specific Study Stoppi[INVESTIGATOR_68261]:  
 
- Two participants experience seizures  
-One or more participant  experiences status epi[INVESTIGATOR_7397]  
 -One or more participant  attempts or commits suicide  during treatment weeks in Phase I or II . 
 -Two or more Serious Adverse Events in one or more participants . 
-Two or more participants have blurred vision associated with rTMS  treatment (confirmed by [CONTACT_68305].)  
8.6 Medical Monitoring  
 
The PI/sponsor ([CONTACT_68314]) has oversight and accountability for the overall safety of the study 
participants.  PI/sponsor safety monitoring will include careful assessment and appropriate 
reporting of adverse events as noted above, as well as the construction and implementation of a 
data and safety -monitoring plan.  Medical monitoring will include a regular assessment of the 
number and type of serious adverse events.  
8.6.[ADDRESS_74469] of 1996 (HIPAA).  
Those regulations require a signed Participant  authorization informing the Participant  of the 
following:  
• What protected health information (PHI) will be collected from Participant s in this study  
• Who will have access to that information and why  
• Who will use or disclose that information  
• The rights of a research Participant  to revoke their authorization for use of their PHI.  
In the event that a Participant  revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability to use all information collected prior to the revocation of 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74470] vital status (long term survival 
status that the Participant  is alive) at the end of their scheduled study period.  
9.2 Source Documents  
 
Source data comprise  all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  Source 
data are contained in source documents.  Examples of these original documents, and data records 
include: hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, Participant s’ 
diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copi[INVESTIGATOR_10379], 
microfiches, photographic negatives, microfilm or magnetic media, x -rays, Participant  files, and 
records kept at the pharmacy, at the laboratories, and at medico -technical departments involved 
in the clinical trial. When applicable, information recorded on the CRF shall match the Source 
Data recorded on the Source Documents.  
 
All clinical notes and discussions regarding the patient will be appropriately captured, signed and 
documented.  
 
9.3 Case Report Forms  
 
An eligibility form will be completed for each Participant  enrolled into the clinical study.  As 
needed, an adverse event worksheet will be completed for study Participant s experiencing AEs.  
The site investigator or designated study staff will review, approve, and sign/date each 
completed CRF; the signature [CONTACT_68313], accurate, and authentic.   Data will be entered into an excel database.  
 
9.4   Data Management  
 
a) Data is entered into an excel spreadsheet  
b) Study data will be reviewed regularly by [CONTACT_68306]:  
a. Participant inclusion criteria has been met  
b. Transcription of data is accurate and complete  
c. Units of measure are recorded appropriately  
c) Details of the study treatments including treatment parameters, such as percent of MT for 
each treatment, will be retained within the TMS device by [CONTACT_68307].  In 
addition, a daily summary of the treatment will be created and stored in the Participant ’s 
source document.  
d) Case files will be created for each Participant  where completed visit CRFs will be stored.  
Any adverse event CRFs will also be stored in the case file.  
 
9.5   Data Security and Confidentiality  
 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
61 
 a) Non-electronic source document data will be stored in a locked cabinet in a secure office. 
Only authorized study staff will have access.  
b) Electronic data will be stored on a secure database. Only authorized users will have 
access. All users will have unique identifiers and passwords. Sharing of log -in 
information is not permitted.  
 
9.[ADDRESS_74471] of 
the study.  These will include Participant  case histories and regulatory documents.  
 
 
The sponsor -investigator will retain the specified records and reports for : 
1. Up to 2 years after the marketing application is approved for the drug; or, if a marketing 
application is not submitted or approved for the drug, until 2 years after shipment and 
delivery of the drug for investigational use is  discontinued and the FDA has been so 
notified.  OR 
2. As outlined in the Mayo Clinic Research Policy Manual –“Retention of and Access to 
Research Data Policy” ,  
whichever is longer.  
 
[ADDRESS_74472] operating procedures.  
 
10.2 Auditing and Inspecting  
The sponsor -investigator will permit study -related monitoring, audits, and inspections by [CONTACT_5040], the monitor , and government regulatory agencies, of all study related documents (e.g. , 
source documents, regulatory documents, data collection instruments, study data etc.).  The 
sponsor -investigator will ensure the capability for inspections of applicable study -related 
facilities (e.g. , pharmacy, diagnostic laboratory, etc.).  
 
Participation as a  sponsor -investigator in this study implies acceptance of potential inspection by 
[CONTACT_5152].  
11 Ethical Considerations  
 
This study is to be conducted according to [LOCATION_002] government regulations and 
Institutional research policies and procedures.  
 

Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
62 
 Although this study is considered more than minimal risk to adolescents, TMS treatments (1 Hz, 
10 Hz, cTBS, and iTBS) offer a potential direct benefit for the individual Participant .  In 
addition, the schedule of mood assessments and daily assessment during the interventional 
portion of the study for any adverse events has been developed for the purpose of monitoring the 
Participant 's well -being.   
 
This protocol and any amendments will be submitted to a properly constituted local IRB, in 
agreement with local legal prescriptions, for formal approval of the study at each participating 
site.  The decision of the IRB concerning the conduct of the study at MUSC will be documented 
in writing to the regulatory sponsor before commencement of this study.  
 
All families and Participant s for this study will be provided a consent/assent form describing this 
study and providing sufficient information for Participant s to make an informed decision about 
their participation in this study.  This consent/assent form will be submitted with the protocol for 
review and approval by [CONTACT_68308].  The formal consent of a Participant , using the 
approved IRB consent/assent form, must be obtained before that Participant  undergoes any study 
procedure.  This form must be signed and dated by [CONTACT_68302] , the Participant ’s legally -
authorized representative, and the individual obtaining informed consent/assent.  
 
12 Study Finances  
12.1 Funding Source  
 
The study  will be funded by a National Institute of Mental Health Grant 1R01MH113700 .  
Neuronetics , Inc. will provide grant -in-kind support for NeuroStar magnetic stimulators and 
disposable SenStar Shields.  
 
12.2 Participant  Stipends or Payments  
 
Participants will be remunerated $[ADDRESS_74473] with costs related to travel.  
 
13 Publication Plan  
 
The PI/Sponsor ([CONTACT_68314]) holds the primary responsibility for publications of results from 
the proposed study .  The PI/Sponsor will register the study on ClinicalTrials.gov 
(https://register.clinicaltrials.gov/ ) prior to participant recruitment and enrollment.  Results will 
be posted to ClinicalTrials.gov within 12 months of final data collection form the primary 
outcomes.  
 
14 References  
 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
63 
 1. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of 
major depression in a national community sample: the National Comorbidity Survey. Am 
J Psychiatry. 1994;151(7):979 -986. 
2. Demyttenaere K, Bruffaerts R, Posada -Villa J, et al. Prevalence, severity, and unmet need 
for treatment of mental disorders in the World Health Organization World Mental Health 
Surveys. Jama. 2004;291(21):2581 -2590.  
3. March JS, Silva S, Petrycki S, et al. The Treatment for Adolescents With Depression 
Study (TADS): long -term effectiveness and safety outcomes. Archives of general 
psychiatry. 2007;64(10):1132 -1143.  
4. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with 
antidepressant drugs. Archives of general psychiatry. 2006;63(3):332 -339. 
5. Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of 
antidepressants for major depressive disorder in children and adolescents: a network 
meta -analysis. Lancet. 2016.  
6. Walkup JT. Antidepressant Efficacy for Depression in Children and Adolescents: 
Industry - and NIMH -Funded Studies. Am J Psychiatry. 2017;174(5):430 -437. 
7. Sakolsky D, Birmaher B. Developmentally informed pharmacotherapy for child and 
adolescent depressive disorders. Child and adolescent psychiatric clinics of North 
America. 2012;21(2):313 -325, viii.  
8. Insel TR. The NIMH experimental medicine initiative. World Psychiatry. 
2015;14(2):151 -153. 
9. Garvey M, Avenevoli S, Anderson K. The National Institute of Mental Health Research 
Domain Criteria and Clinical Research in Child and Adolescent Psychiatry. J Am Acad 
Child Adolesc Psychiatry. 2016;55(2):[ADDRESS_74474] of physical and sexual abuse on 
treatment response in the Treatment of Resistant Depression in Adolescent Study 
(TORDIA). J Am Acad Child Adolesc Psychiatry. 2011;50(3):293 -301. 
11. McMakin DL, Olino TM, Porta G, et al. Anhedonia predicts poorer recovery among 
youth with selective serotonin reuptake inhibitor treatment -resistant depression. J Am 
Acad Child Adolesc Psychiatry. 2012;51(4):404 -411. 
12. Gabbay V, Johnson AR, Alonso CM, Evans LK, Babb JS, Klein RG. Anhedonia, but not 
irritability, is associated with illness severity outcomes in adolescent major depression. J 
Child Adolesc Psychopharmacol. 2015;25(3):194 -200. 
13. Brambilla P, Perez J, Barale F, Schettini G, Soares JC. GABAergic dysfunction in mood 
disorders. Mol Psychiatry. 2003;8(8):721 -737, 715.  
14. Croarkin PE, Levinson AJ, Daskalakis ZJ. Evidence for GABAergic inhibitory deficits in 
major depressive disorder. Neurosci Biobehav Rev. 2011;35(3):818 -825. 
15. Vaiva G, Thomas P, Ducrocq F, et al. Low posttrauma GABA plasma levels as a 
predictive factor in the development of acute posttraumatic stress disorder. Biological 
psychiatry. 2004;55(3):250 -254. 
16. Gabbay V, Mao X, Klein RG, et al. Anterior cingulate cortex gamma -aminobutyric acid 
in depressed adolescents: relationship to anhedonia. Archives of general psychiatry. 
2012;69(2):139 -149. 
17. Wagner JJ, Alger BE. GABAergic and developmental influences on homosynaptic LTD 
and depotentiation in rat hippocampus. The Journal of neuroscience : the official journal 
of the Society for Neuroscience. 1995;15(2):1577 -1586.  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
64 
 18. Price JL, Drevets WC. Neurocircuitry of mood disorders. Neuropsychopharmacology. 
2010;35(1):[ADDRESS_74475] of stress on the structure of the adolescent brain: Implications for 
adolescent mental health. Brain research. 2016.  
20. Zhang W, Rosenkranz JA. Effects of Repeated Stress on Age -Dependent GABAergic 
Regulation of the Lateral Nucleus of the Amygdala. Neuropsychopharmacology. 
2016;41(9):2309 -2323.  
21. Gilad GM, Gilad VH, Wyatt RJ, Tizabi Y. Region -selective stress -induced increase of 
glutamate uptake and release in rat forebrain. Brain research. 1990;525(2):335 -338. 
22. Lowy MT, Gault L, Yamamoto BK. Adrenalectomy attenuates stress -induced elevations 
in extracellular glutamate concentrations in the hippocampus. Journal of neurochemistry. 
1993;61(5):1957 -1960.  
23. Fontella FU, Vendite DA, Tabajara AS, et al. Repeated restraint stress alters hippocampal 
glutamate uptake and release in the rat. Neurochemical research. 2004;29(9):1703 -1709.  
24. Ehrlich DE, Ryan SJ, Rainnie DG. Postnatal development of electrophysiological 
properties of principal neurons in the rat basolateral amygdala. The Journal of 
physiology. 2012;590(19):4819 -4838.  
25. Ehrlich DE, Ryan SJ, Hazra R, Guo JD, Rainnie DG. Postnatal maturation of GABAergic 
transmission in the rat basolateral amygdala. Journal of neurophysiology. 
2013;110(4):926 -941. 
26. Ziemann U. Pharmacology of TMS. Supplements to Clinical neurophysiology. 
2003;56:226 -231. 
27. Maddock RJ, Buonocore MH. MR spectroscopic studies of the brain in psychiatric 
disorders. Current topi[INVESTIGATOR_68262]. 2012;11:199 -251. 
28. Ziemann U, Reis J, Schwenkreis P, et al. TMS and drugs revisited 2014. Clin 
Neurophysiol. 2015;126(10):1847 -1868.  
29. Krnjevic K, Randic M, Straughan DW. Nature of a cortical inhibitory process. The 
Journal of physiology. 1966;184(1):49 -77. 
30. Krnjevic K, Randic M, Straughan DW. An inhibitory process in the cerebral cortex. The 
Journal of physiology. 1966;184(1):16 -48. 
31. Kujirai T, Caramia MD, Rothwell JC, et al. Corticocortical inhibition in human motor 
cortex. The Journal of physiology. 1993;471:501 -519. 
32. Croarkin PE, Wall CA, Lee J. Applications of transcranial magnetic stimulation (TMS) in 
child and adolescent psychiatry. Int Rev Psychiatry. 2011;23(5):445 -453. 
33. Donaldson AE, Gordon MS, Melvin GA, Barton DA, Fitzgerald PB. Addressing the 
needs of adolescents with treatment resistant depressive disorders: a systematic review of 
rTMS. Brain Stimul. 2014;7(1):[ADDRESS_74476] -Lefaucheur I, Keravel Y, Nguyen JP. Motor cortex 
rTMS restores defective intracortical inhibition in chronic neuropathic pain. Neurology. 
2006;67(9):1568 -1574.  
35. Baeken C, De Raedt R. Neurobiological mechanisms of repetitive transcranial magnetic 
stimulation on the underlying neurocircuitry in unipolar depression. Dialogues in clinical 
neuroscience. 2011;13(1):139 -145. 
36. Dubin MJ, Mao X, Banerjee S, et al. Elevated prefrontal cortex GABA in patients with 
major depressive disorder after TMS treatment measured with proton magnetic resonance 
spectroscopy. Journal of psychiatry & neuroscience : JPN. 2016;41(3):E37 -45. 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
65 
 37. Perera T, George MS, Grammer G, Janicak PG, Pascual -Leone A, Wirecki TS. The 
Clinical TMS Society Consensus Review and Treatment Recommendations for TMS 
Therapy for Major Depressive Disorder. Brain Stimul. 2016;9(3):336 -346. 
38. McClintock SM, Reti IM, Carpenter LL, et al. Consensus Recommendations for the 
Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the 
Treatment of Depression. The Journal of clinical psychiatry. 2017.  
39. Cohen H, Kaplan Z, Kotler M, Kouperman I, Moisa R, Grisaru N. Repetitive transcranial 
magnetic stimulation of the right dorsolateral prefrontal cortex in posttraumatic stress 
disorder: a double -blind, placebo -controlled study. Am J Psychiatry. 2004;161(3):515 -
524. 
40. Eche J, Mondino M, Haesebaert F, Saoud M, Poulet E, Brunelin J. Low - vs High -
Frequency Repetitive Transcranial Magnetic Stimulation as an Add -On Treatment for 
Refractory Depression. Front Psychiatry. 2012;3:13.  
41. Brunelin J, Jalenques I, Trojak B, et al. The efficacy and safety of low frequency 
repetitive transcranial magnetic stimulation for treatment -resistant depression: the results 
from a large multicenter French RCT. Brain Stimul. 2014;7(6):855 -863. 
42. Hesselberg ML, Wegener G, Buchholtz PE. Antidepressant efficacy of high and low 
frequency transcranial magnetic stimulation in the FSL/FRL genetic rat model of 
depression. Behavioural brain research. 2016;314:45 -51. 
43. Kimbrell TA, Little JT, Dunn RT, et al. Frequency dependence of antidepressant 
response to left prefrontal repetitive transcranial magnetic stimulation (rTMS) as a 
function of baseline cerebral glucose metabolism. Biological psychiatry. 
1999;46(12):1603 -1613.  
44. Kozel FA, Tian F, Dhamne S, et al. Using simultaneous repetitive Transcranial Magnetic 
Stimulation/functional Near Infrared Spectroscopy (rTMS/fNIRS) to measure brain 
activation and connectivity. NeuroImage. 2009;47(4):[ADDRESS_74477]. 2004;82(1):71 -76. 
46. Hecht D. Depression and the hyperactive right -hemisphere. Neuroscience research. 
2010;68(2):77 -87. 
47. Lefaucheur JP, Andre -Obadia N, Antal A, et al. Evidence -based guidelines on the 
therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin 
Neurophysiol. 2014;125(11):[ADDRESS_74478], roots and peripheral nerves: Basic principles and procedures for 
routine clinical and research application. An updated report from an I.F.C.N. Committee. 
Clin Neurophysiol. 2015;126(6):1071 -1107.  
49. !!! INVALID CITATION !!! .  
50. Davis NJ. Transcranial stimulation of the developi[INVESTIGATOR_38866]: a plea for extreme caution. 
Front Hum Neurosci. 2014;8:600.  
51. Geddes L. Brain stimulation in children spurs hope - and concern. Nature. 
2015;525(7570):436 -437. 
52. Croarkin PE, Rotenberg A. Pediatric Neuromodulation Comes of Age. J Child Adolesc 
Psychopharmacol. 2016;26(7):578 -581. 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
66 
 53. Croarkin PE, Nakonezny PA, Lewis CP, et al. Developmental aspects of cortical 
excitability and inhibition in depressed and healthy youth: an exploratory study. Front 
Hum Neurosci. 2014;8:669.  
54. Downar J, Geraci J, Salomons TV, et al. Anhedonia and reward -circuit connectivity 
distinguish nonresponders from responders to dorsomedial prefrontal repetitive 
transcranial magnetic stimulation in major depression. Biological psychiatry. 
2014;76(3):176 -185. 
55. Duncan NW, Hayes DJ, Wiebking C, et al. Negative childhood experiences alter a 
prefrontal -insular -motor cortical network in healthy adults: A preliminary multimodal 
rsfMRI -fMRI -MRS -dMRI study. Human brain mappi[INVESTIGATOR_007]. 2015;36(11):4622 -4637.  
56. Fonzo GA, Huemer J, Etkin A. History of childhood maltreatment augments dorsolateral 
prefrontal processing of emotional valence in PTSD. Journal of psychiatric research. 
2016;74:45 -54. 
57. Gorwood P. Neurobiological mechanisms of anhedonia. Dialogues in clinical 
neuroscience. 2008;10(3):291 -299. 
58. Skirzewski M, Lopez W, Mosquera E, et al. Enhanced GABAergic tone in the ventral 
pallidum: memory of unpleasant experiences? Neuroscience. 2011;196:131 -146. 
59. John CS, Smith KL, Van't Veer A, et al. Blockade of astrocytic glutamate uptake in the 
prefrontal cortex induces anhedonia. Neuropsychopharmacology. 2012;37(11):2467 -
2475.  
60. Spencer AE, Uchida M, Kenworthy T, Keary CJ, Biederman J. Glutamatergic 
dysregulation in pediatric psychiatric disorders: a systematic review of the magnetic 
resonance spectroscopy literature. The Journal of clinical psychiatry. 2014;75(11):1226 -
1241.  
61. Haroon E, Fleischer CC, Felger JC, et al. Conceptual convergence: increased 
inflammation is associated with increased basal ganglia glutamate in patients with major 
depression. Mol Psychiatry. 2016;21(10):1351 -1357.  
62. Reich CG, Mihalik GR, Iskander AN, Seckler JC, Weiss MS. Adolescent chronic mild 
stress alters hippocampal CB1 receptor -mediated excitatory neurotransmission and 
plasticity. Neuroscience. 2013;253:444 -454. 
63.       Marjanska M, Lehericy S, Valabregue R, et al. Brain dynamic neurochemical changes in 
dystonic patients: a magnetic resonance spectroscopy study. Movement disorders : 
official journal of the Movement Disorder Society. 2013;28(2):201 -209. 
64.       Tremblay S, Beaule V, Proulx S, et al. Relationship between transcranial magnetic 
stimulation measures of intracortical inhibition and spectroscopy measures of GABA and 
glutamate+glutamine. Journal of neurophysiology. 2013;109(5):1343 -134. 
65. Croarkin PE, Nakonezny PA, Husain MM, et al. Evidence for increased glutamatergic 
cortical facilitation in children and adolescents with major depressive disorder. JAMA 
Psychiatry. 2013;70(3):291 -299. 
66. Wall CA, Croarkin PE, Sim LA, et al. Adjunctive use of repetitive transcranial magnetic 
stimulation in depressed adolescents: a prospective, open pi[INVESTIGATOR_799]. The Journal of 
clinical psychiatry. 2011;72(9):1263 -1269.  
67. Croarkin PE, Wall CA, Nakonezny PA, et al. Increased cortical excitability with 
prefrontal high -frequency repetitive transcranial magnetic stimulation in adolescents with 
treatment -resistant major depressive disorder. J Child Adolesc Psychopharmacol. 
2012;22(1):56 -64. 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
67 
 68. Wall CA, Croarkin PE, McClintock SM, et al. Neurocognitive effects of repetitive 
transcranial magnetic stimulation in adolescents with major depressive disorder. Front 
Psychiatry. 2013;4:165.  
69. Wall CA, Croarkin PE, Maroney -Smith MJ, et al. Magnetic Resonance Imaging -Guided, 
Open -Label, High -Frequency Repetitive Transcranial Magnetic Stimulation for 
Adolescents with Major Depressive Disorder. J Child Adolesc Psychopharmacol. 
2016;26(7):582 -589. 
70. Croarkin PE, Nakonezny PA, Wall CA, et al. Transcranial magnetic stimulation 
potentiates glutamatergic neurotransmission in depressed adolescents. Psychiatry Res. 
2016;247:25 -33. 
71. Vaiva G, Boss V, Ducrocq F, et al. Relationship between posttrauma GABA plasma 
levels and PTSD at 1 -year follow -up. Am J Psychiatry. 2006;163(8):1446 -1448.  
72. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design 
issues. J Natl Cancer Inst. 2010;102(3):[ADDRESS_74479] stimulation 
vs. single and paired pulse transcranial magnetic stimulation: a comparative study of 165 
pediatric subjects. Front Hum Neurosci. 2015;9:29.  
74. Rossi S, Hallett M, Rossini PM, Pascual -Leone A. Safety, ethical considerations, and 
application guidelines for the use of transcranial magnetic stimulation in clinical practice 
and research. Clin Neurophysiol. 2009;120(12):2008 -2039.  
75. Krishnan C, Santos L, Peterson MD, Ehinger M. Safety of noninvasive brain stimulation 
in children and adolescents. Brain Stimul. 2015;8(1):76 -87. 
76. Kirton A, Deveber G, Gunraj C, Chen R. Neurocardiogenic syncope complicating 
pediatric transcranial magnetic stimulation. Pediatric neurology. 2008;39(3):196 -197. 
77. Wall C, Croarkin P, Bandel L, Schaefer K. Response to repetitive transcranial magnetic 
stimulation induced seizures in an adolescent patient with major depression: a case 
report. Brain Stimul. 2014;7(2):337 -338. 
78. Hu SH, Wang SS, Zhang MM, et al. Repetitive transcranial magnetic stimulation -induced 
seizure of a patient with adolescent -onset depression: a case report and literature review. 
The Journal of international medical research. 2011;39(5):2039 -2044.  
79. Chiramberro M, Lindberg N, Isometsa E, Kahkonen S, Appelberg B. Repetitive 
transcranial magnetic stimulation induced seizures in an adolescent patient with major 
depression: a case report. Brain Stimul. 2013;6(5):830 -831. 
80. Cullen KR, Jasberg S, Nelson B, Klimes -Dougan B, Lim KO, Croarkin PE. Seizure 
Induced by [CONTACT_68309]. J 
Child Adolesc Psychopharmacol. 2016;26(7):[ADDRESS_74480] transcranial magnetic stimulation in children. Developmental medicine and 
child neurology. 2012;54(7):636 -639. 
82. Wu SW, Maloney T, Gilbert DL, et al. Functional MRI -navigated repetitive transcranial 
magnetic stimulation over supplementary motor area in chronic tic disorders. Brain 
Stimul. 2014;7(2):[ADDRESS_74481] I. Safety of Transcranial Magnetic Stimulation in Children: 
A Systematic Review of the Literature. Pediatric neurology. 2017;68:[ADDRESS_74482] stimulation: a new form of TMS 
treatment for depression? Depress Anxiety. 2015;32(3):182 -192. 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74483] stimulation in 
refractory depression: a randomized sham -controlled study. Brain : a journal of 
neurology. 2014;137(Pt 7):2088 -2098.  
86. Gershon RC, Wagster MV, Hendrie HC, Fox NA, Cook KF, Nowinski CJ. NIH toolbox 
for assessment of neurological and behavioral function. Neurology. 2013;80([ADDRESS_74484] 
3):S2 -6. 
87. Mir-Moghtadaei A, Caballero R, Fried P, et al. Concordance Between BeamF3 and MRI -
neuronavigated Target Sites for Repetitive Transcranial Magnetic Stimulation of the Left 
Dorsolateral Prefrontal Cortex. Brain Stimul. 2015;8(5):965 -973. 
88. Research USDoHaHSFaDACfDaRHCFBEa. Design Considerations for Pi[INVESTIGATOR_68263], Clinical Investigators, 
Intitutional Review Boards, and Food and Drug Administration Staff. 2013. Accessed 
October 8, 2016.  
89. PASS 14 Power Analysis and Sample Size Software  [computer program]. Kaysville, Utah, 
[LOCATION_003]: NCSS, LLC.; 2016.  
90. Tsonaka R, Verbeke G, Lesaffre E. A semi -parametric shared parameter model to handle 
nonmonotone nonignorable missingness. Biometrics. 2009;65(1):81 -87. 
 
  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  [ADDRESS_74485] should not be considered exhaustive . Drugs that are categorized into one of the drug 
categories listed in the table below will be treated similarly.   
 
CLASS:      Drug  PRN  Chronic  
ANTIASTHMA DRUGS    
  Theo -Dur (theophylline)  N N 
 Bronchodilators    
  Alupent (metaproterenol), Proventil (albuterol), Ventolin (albuterol)  Y Y 
 Steroids    
  Inhaled (Beclovent [beclomethasone], Azmacort [triamcinolone], 
Vanceril [beclomethasone])  Y Y 
  Oral Y Y 
 Leukotriene antagonists    
  Accolate (zafirlukast), Zyflo (zileuton), Singulair (monoleukast)  N Y 
     
ANTICOAGULANTS    
  Coumadin (warfarin)  N Y  
(w/ stable 
protime)  
     
ANTICHOLINGERGICS    
  Cogentin (benztropi[INVESTIGATOR_050]), Artane (trihexyphenidyl), etc.  N N 
  Phenylpropanolamine (PPA) and pseudoephedrine  N N 
     
ANTIHISTAMINE and DECONGESTANTS    
 Sedating    
  Anticholinergic (Benadryl [diphenhydramine], chlorpheniramine, 
brompheniramine, Atarax [hydroxyzine]) (not for psychiatric indications)  N N 
 Non-sedating    
  Allegra (fexofenadine), Claritin (loratadine), Zyrtec (cetirizine)  Y Y 
  Hismanal (astemizole)  N N 
     
ANTI -INFECTIVE AGENTS    
 Antibacterial antibiotics (Penicillin, sulfa, etc.)  Y Y 
 Antifungal agents  (ketoconazole, fluconazole, etc.)    
  Topi[INVESTIGATOR_17131]  Y Y 
  Oral antifungals (single -dose for vaginitis OK)  Y N 
 Antiviral agents    
  Zovirax (acyclovir), Famvir (famcyclovir), Valtrex (valacyclovir)  Y Y 
  Antiretroviral drugs (e.g. AZT, protease inhibitors)  N N 
     
ANTI -NEOPLASTIC AGENTS  N N 
     
SKELETAL MUSCLE RELAXANTS    
  Lioresal (baclofen), Flexeril (cyclobenzaprine), Parafon Forte 
(chlorzoxazone), Robaxin (methocarbamol), Soma (carisoprodol)  N N 
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
70 
 CLASS:      Drug  PRN  Chronic  
ANALGESICS AND ANTIPYRETICS    
  Nonsteroidal anti -inflammatory agents (aspi[INVESTIGATOR_248], ibuprofen, naproxen)  Y Y 
  Opi[INVESTIGATOR_17132] / Partial Agonists (including Ultram [tramadol])  N N 
  Miscellaneous analgesics & antipyretics (acetaminophen, paracetamol)  Y Y 
 
CARDIOVASCULAR DRUGS (All drugs in this category must be stable for at least 3 months)  
CARDIAC DRUGS    
  Calcium Channel Blockers  for coronary disease or angina (see also 
"Antihypertensives") (Calan [verapamil], Cardizem [diltiazem], Norvasc 
[amlodipi[INVESTIGATOR_050]], Procardia [nifedipi[INVESTIGATOR_050]])  N Y 
 Antiarrhythmics    
  Cordarone (amiodarone), lidocaine (note: local anesthesia injection OK), 
Mexitil (mexiletine), Norpace (disopyramide), Procan (procainamide), 
quinidine, Tambocor (flecainide)  N N 
  Digoxin (blood levels must be monitored)  N Y 
     
ANTI -HYPERTENSIVE AGENTS  (All anti -hypertensives must be stable dose x 1 month)  
  ACE Inhibitors (Vasotec, Capoten, Zestril)  N Y 
  Angiotensin receptor blockers (Cozaar)  N Y 
  Calcium Channel Blockers  N Y 
  Diuretics  Y Y 
  Phentolamine  N N 
Beta -Adrenergic Blockers (see also  Anti-Migraine )   
  Low lipid solubility/CNS penetration  (Corgard [nadolol], Tenormin 
[atenolol])  Y Y 
  High lipid solubility/CNS penetration  (Inderal [propranolol], Lopressor 
[metaprotereno]), (low lipid solubility preferred)  Y Y 
 Peripherally -acting alpha adrenergic agents    
  Cardura (doxazosin), Hytrin (terazosin), Minipress (prazosin)  Y Y 
 Centrally -acting alpha adrenergic agents    
  Aldomet (methyldopa), Catapres (clonidine)  N N 
 All others  (quanethidine, reserpi[INVESTIGATOR_050], etc.)  N N 
     
ANTILIPEMIC AGENTS    
  Niacin (no slow -release preparations), Lipi[INVESTIGATOR_17133] (atorvastatin), Lopid 
(gemfibrozil), Mevacor (lovastatin), Zocor (simvastatin)  N Y 
     
VASODILATING AGENTS    
  Hydralazine  N Y 
  minoxidil (topi[INVESTIGATOR_17134])  N C 
     
ANTI -CONVULSANTS  N N 
  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
71 
 CLASS:      Drug  PRN  Chronic  
PSYCHOTHERAPEUTIC AGENTS    
  Antidementia drugs (donepezil, etc.), Antidepressants, Antipsychotics 
(Thorazine, Prolixin, etc.), Miscellaneous Psychotherapeutic Agents  N N 
 Anxiolytics (per protocol)  Y N 
 Stimulants  N  
 Sedatives and Hypnotics    
  Barbiturates, Benzodiazepi[INVESTIGATOR_1651] (except those allowed per the protocol), 
Other hypnotic agents  N N 
  Ambien (zolpi[INVESTIGATOR_6730]; per protocol), chloral hydrate (per protocol), Sonata 
(zaleplon; per protocol), Lunesta (eszopi[INVESTIGATOR_11123]; per protocol), Rozerem 
(ramelteon; per protocol)  Y N 
     
ANTIMANIC AGENTS    
  Anticonvulsants, lithium  N N 
     
HORMONES & SYNTHETIC SUBSTITUTES    
  Corticosteroids (methylprednisolone, prednisone)  Y N 
  Mineralocorticoids (Florinef [fludrocortisone])  N N 
  Topi[INVESTIGATOR_8826] (creams, ointments, eyedrops)  Y Y 
  pregnenolone  N N 
 Androgens  N N 
  DHEA, testosterone, danazol  N N 
 Contraceptives    
  Hormonal (dose must be stable for at least 3 months) : Oral, Vaginal 
Ring, Patch, Injections, Norplant (levonorgestrel)  N Y 
  Intrauterine device  Y Y 
  Latex condom , diaphragm and or cervical cap with spermicide  Y Y 
 Estrogen replacement  (postmenopausal, stable dose for 3 months)  N Y 
 Thyroid (stable dose for 3 months and thyroid function tests within normal 
limits.  Clinical significance to be determined by [CONTACT_099])  N Y 
     
ANTIDIABETIC AGENTS    
  Oral hypoglycemic agents  N Y 
  Insulin’s  Y Y 
   
DERMATOLOGIC AGENTS    
  Topi[INVESTIGATOR_17135], Rogaine (topi[INVESTIGATOR_8580]), Miscellaneous 
creams, ointments, etc.  Y Y 
     
VITAMINS  Y Y 
   
OVER -THE-COUNTER SUPPLEMENTS    
  chromium pi[INVESTIGATOR_17136], DHEA, melatonin, pregnenolone, St. John’s Wort  N N 
     
 
  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
72 
 CLASS:      Drug  PRN  Chronic  
GASTROINTESTINAL DRUGS    
  Cisapride (propulsid)  Y Y 
 Antiemetics    
  Over -the-counter (e.g., Emetrol [dextrose], Coke syrup)  Y Y 
  Phenothiazines & related drugs (Compazine [prochloroperazine], 
Phenergan [promethazine], Reglan [metoclopramide], Tigan 
[trimethobenzamide]), Anzemet (dolasetron), Kytril (granisetron), Zofran 
(ondansetron)  Y N 
  Marinol (dronabinol),  N N 
 Antacids    
  AlternaGel  (aluminum hydroxide), Amphojel (aluminum hydroxide), 
Basaljel (aluminum carbonate), Bicitra (sodium citrate), Maalox (calcium 
carbonate), MagOX (magnesium oxide), Mylanta (magnesium 
hydroxide), Tums (calcium carbonate), UroMag (magnesium oxide)  Y Y 
 Antidiarrhea agents    
  Arco-Lase (trizyme), Furoxone (furazolidone), Motofen (difenoxin), 
Sandostatin (octreotide acetate)  N N 
  Imodium (loperamide), Lomotil (diphenoxylate), Pepto -Bismol (bismuth 
subsalicylate)  Y N 
 Cathartics & Laxatives    
  Colace (docusate), enemas, Metamucil, Perdiem, Senokot, Soflax, 
Unifibre  Y Y 
  Dialose (docusate)  Y Y 
 Antisecretory agents    
 H2 Blockers  N N 
  Axid (nizatidine), Pepcid (famotidine), Zantac (ranitidine)  Y Y 
 Proton pump inhibitors    
  Prevacid (lansoprazole), Prilosec (omeprazole)  Y Y 
 Miscellaneous gastrointestinal drugs    
  Carafate (sucralfate)  Y Y 
  Reglan (metoclopramide)  N N 
  Levsin (L -hyoscyamine sulfate)  Y Y 
     
ANTI -MIGRAINE    
  DHE 45 (dihydroergotamine), Imitrex (sumatriptan), methysergide, 
Midrin (isometheptene mucate), Zomig (zolmitriptan)  N Y 
  Fiorinal (butalbital, ASA, caffeine), Cafergot (ergotamine)  Y Y 
  Nonsteroidal anti -inflammatory drugs (ibuprofen, naproxen, Toradol, 
etc.) Y Y 
 Beta -blocking drugs    
  Corgard (nadolol), Tenormin (atenolol), Other beta -blockers (e.g., 
Inderal [propranolol])  Y Y 
     
SKIN & MUCOUS MEMBRANE AGENTS  Y Y 
     
  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
73 
 CLASS:      Drug  PRN  Chronic  
MISCELLANEOUS DRUGS    
  Accutane , All over -the-counter diet pi[INVESTIGATOR_3353],  Ionamin (phentermine resin), 
Lioresal (baclofen), Wellbutrin (bupropi[INVESTIGATOR_2394]), Zyban (bupropi[INVESTIGATOR_2394])  N N 
  Allopurinol, colchicine  Y Y 
  Fosamax (alendronate)  N Y 
  Gold compounds, hydroxychloroquine, and methotrexate for severe 
arthritis  N Y 
  Smoking cessation aids ( Nicorette , nicotine patches)  Y Y 
  Chantix (varenicline)  N N 
     
ENDNOTES    
N = Never to be used in this study.  
Y = Can be used in this study for either PRN or Chronic use as indicated in the table.  
C = Call for Sponsor approval.  Approval for these medications is generally granted if the patient is 
otherwise acceptable, including stable medical condition, no undue risk, no other "marginal" 
considerations in the medical history or concomitant medications. Or may be used during the long -term 
maintenance phase with certain restrictions.  
 
16 Appendix B  ICF and TMS Measures  
 
Collection of ICF and TMS Neurophysiology Measures  
 
1) The subject is greeted and seated comfortably.  
 
2) Details of the subject’s session will be recorded in the study file.  
 
3) Subjects, technicians, and the study physician (who will always be present) will be provided with 
earplugs, which are to be worn at all times. Subjects will be instructed to turn off all cell phones 
and pagers. Eyeglasses will be removed. Subjects should not have any metal above their 
neckline (with the exception of orthodontics), specifically hairpi[INVESTIGATOR_68264]. 
Subjects will be instructed to sit quietly with their eyes open throughout the measurements.  
 
4) The TMS coil will be wiped with an alcohol swab before and after each session.  
 
5) EMG set up includes a 1k gain, HPF 30, and LPF [ADDRESS_74486] ensure that the switch of the bioelectric amplifier is on.  
 
Connecting EMG Leads:  
 
a. EMG leads are connected to the right hand.  
b. The white wire goes in the red circle.  
c. The black wire goes in the green circle.  
d. The green wire goes in the white circle (this is the ground).  
e. Place one electrode on abductor pollicis brevis (white wire).  
f. Place one lead on the middle joint of the index finger (black wire).  
g. Place ground lead on the hand that you are measuring (green wire).  
h. On the computer, the red line refers to the right hand.  
Adolescent Biomarker Guided rTMS  Mayo Clinic IRB # 17 -004958   
 Version  6 Date:  26 July 2021  
  
74 
 6) At the start of each session, the operator must check the plastic casing of the stimulating coil for 
any signs of external damage. If any cracks are visible in the housing, the stimulating coil must 
not be used and should be serviced.  
 
7) Connect the coil to the main Magstim unit. Switch on, select the desired stimulating power by 
[CONTACT_68310], and press the run switch on the front panel of the Magstim to arm 
the unit. The Magstim will charge and the “ready” display will be illuminated.  
 
8) Position the stimulating coil on the desired area to be stimulated. Press and hold down one or 
both of the safety switches at the baseline of the stimulating coil. Triggering the Magstim results 
in a magnetic pulse being delivered by [CONTACT_68311], stimulating the nerves beneath it.  
 
9) When necessary, reposition the stimulating coil and/or modify the stimulating power level to suit 
the requirements for the next stimulus. Meanwhile, the Magstim will have recharged and can be 
triggered once again in the normal manner.  
 
10) When the tests have been completed, press the “stop” switch on the front panel of the Magstim 
and replace the stimulating coil on the coil hanger. The Magstim will then revert to standby [CONTACT_68312].  
 
11) The TMS coil is held tangential to the subject’s head at 45 degrees.  
 
12)  Single -pulse measures (MT and CSP):  
 
a. When giving pulses, always wait 5 -10 seconds between pulses.  
b. Start at 30% intensity and administer a few pulses to acclimate the subject to the test 
conditions.  
c. Increase to 40% intensity and then by 10 at a time to get motor responses, and then 
decrease intensity.  
d. Administer 10 successive pulses at each intensity. If 6 of 10 pulses are not sufficient, this 
is the threshold point. If 5 of 10 pulses elicit a motor response, decrease the intensity until 
6 of 10 do not elicit a motor response.  
e. Measure optimal site laterally and posterior from the vertex.  
f. Single -pulse measures are performed with submaximal, tonic, hand muscle contraction. 
This reduces variability in the CSP (Mathis et al. 1998, Bajbouj et al. 2006).  
g. The duration of the CSP is measured from the onset of the corticospi[INVESTIGATOR_68265], to the end of the silent period. The end is the point at which averaged tonic 
EMG activity reaches the amplitude of mean EMG activity prior to TMS.  
 
13) Paired -pulse measures (ICI and ICF):  
 
a. The figure of eight coil and the bistim module are utilized for these measurements.  
b. Two stimulations are given in succession, as described previously (Kujirai et al. 1993, 
Nahas et al. 2007). The first pulse is the conditioning stimulus. The second pulse is the 
test pulse.  
c. Stimulations for ICI are spaced [ADDRESS_74487] response amplitudes.  
 
 